Volume 6; Issue 12

European Journal of Cancer Supplements

Volume 6; Issue 12

1

Editorial Board

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 33 KB

english, 2008

2

Welcome address

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 35 KB

english, 2008

3

Societies' profiles

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 104 KB

english, 2008

4

Conference committees

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 26 KB

english, 2008

5

Acknowledgements

Journal:

European Journal of Cancer Supplements

Year:

2008

File:

PDF, 34 KB

2008

6

Alphabetical list of all supporting companies & organisations

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 27 KB

english, 2008

7

Exhibition floor plan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

8

General information

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 50 KB

english, 2008

9

Scientific programme — overview

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

10

Scientific programme — details

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 566 KB

english, 2008

11

1 INVITED No risk, no fun

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

12

2 INVITED IGF-I as an emerging target

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

13

3 INVITED RET inhibition: therapeutic implications in thyroid cancer

N. Mitsiades, J.A. Fagin, D.G. Pfister

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

14

4 INVITED C-Met as a target in clinical oncology; rationale and current achievements

F.A.L.M. Eskens

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

15

5 INVITED Biological roles of PI 3-kinase isoforms

B. Vanhaesebroeck

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

16

6 INVITED Notch as a potential therapeutic target in cancer

L. Miele, P. Rizzo, C. Osipo, K. Foreman, M. Bocchetta, D. Tonetti

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

17

7 INVITED Developing combination therapies for hormone-refractory prostate cancer in a pre-clinical mouse model of the disease

C. Abate-Shen, C.W. Kinkade, M. Castillo-Martin, C. Cordon-Cardo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

18

8 INVITED Pitfalls for cancer drug discovery with “genetic” animal models

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

19

9 INVITED How naturally occurring cancers in dogs can inform the drug development path

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

20

10 INVITED Imaging signaling pathways in animal models

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

21

11 INVITED Update on the application of the EU paediatric regulation

R. Herold, A. Saint Raymond

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

22

12 INVITED The Pediatric Preclinical Testing Program (PPTP): changing the paradigm for drug development

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

23

13 INVITED KidsCancerKinome: a EU-FP6 project for preclinical kinase inhibitor evaluation as a tool to prioritize compounds for paediatric development

H. Caron, S.C. Clifford, T. Pietsch, C. Lanvers, J. Shipley, M.L. denBoer, O. Delattre, M. Serra, T. Koch, G. Vassal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

24

14 INVITED Early phase drug development in the Children's Oncology Group

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

25

15 INVITED Early drug development in the childrens' clinics in Europe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

26

16 INVITED Pharmacogenomics of anticancer drug disposition: we aren't there yet

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

27

17 INVITED Bioinformatics – from the bench to the bedside and back

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

28

18 INVITED Pharmacogenomics in colon cancer: Fantasy or Reality

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

29

19 INVITED High throughput genotyping and its possible applications in pharmacoepidemiology

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

30

20 INVITED Phase 0 microdosing studies as part of the learn/confirm approach to drug development

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

31

21 INVITED Use of phase 0-changes in cancer drug development

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

32

22 INVITED Implementation of phase 0 trials

J.H.M. Schellens

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

33

23 INVITED Industry perspective

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

34

24 INVITED The evolution of CYPs from metabolising enzymes to potential targets in cancer therapy development

L.H. Patterson, K. Pors, P.M. Loadman, M. Sutherland, J. Gill, H. Sheldrake, S.D. Shnyder

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

35

25 INVITED CYP-activated prodrugs as chemotherapeutics

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

36

26 INVITED Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

A. Reid, G. Attard, N. Babu Oommen, D. Olmos, P. Fong, R. Molife, M. Dowsett, G. Lee, A. Molina, J.S. De-Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

37

27 INVITED Novel atypical retinoic acid metabolism blocking agents (RAMBAs)/ CYP26 inhibitors for breast cancer therapy

L.K. Gediya, P. Purushottamachar, A. Khandelwal, J. Mehta, A. Godbole, V.C.O. Njar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

38

28 INVITED Adaptive phase II trials

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

39

29 INVITED Parallel phase II trials – European perspective

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

40

30 INVITED Patient enrichment strategy in phase II

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

41

31 INVITED Using biomarkers in phase II studies

J. Tabernero, A. Cervantes, J. Baselga

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

42

32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubenstein, L. Shankar, R. Kaplan, D. Lacombe, J. Verweij

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

43

33 ORAL Preclinical evaluation of 64Cu labeled bevacizumab by PET/CT imaging in tumor models

Z. Wang, T. Chang, M. Lane, J. Xiao, T. Rogers

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

44

34 ORAL Advantages of a modified continual reassessment method (CRM) for dose finding studies: experience in ongoing phase I trials with ABT-263

Y. Chiu, C.M. Rudin, G.I. Shapiro, A.W. Roberts, J.R. Brown, W. Wilson, O. O'Connor, H. Xiong, S. Enschede, A. Krivoshik

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

45

35 ORAL Clinical attrition rates for kinase inhibitors in oncology

I. Walker, D.R. Newell

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

46

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

P. Schöffski, A. Awada, H. Dumez, T. Gil, S. Bartholomeus, J. Selleslach, M. Taton, H. Fritsch, N. Peter, G. Munzert

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

47

37 INVITED Drugging the cancer chaperone Hsp90: From chemical biology with natural products to active drugs in the clinic

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

48

38 INTIVED Bortezomib therapy of multiple myeloma

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 68 KB

english, 2008

49

39 INVITED Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer

K. Sakamoto, A. Rodriguez-Gonzalez, K. Cyrus, K.B. Kim, C. Crews, R.J. Deshaies

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

50

40 INVITED Role of autophagy in cancer and therapy

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

51

41 POSTER DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B

N.J. Serkova, J. Spratlin, S.G. Eckhardt, B. Milestone, E.G. Chiorean, H. Youssoufian, F. Fox, E. Rowinsky, R.B. Cohen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

52

42 POSTER NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort

M. Mita, M.A. Spear, L.K. Yee, K.P. Papadopoulos, E.I. Heath, M. Pilat, O. Romero, G.K. Lloyd, A. Mita, P. LoRusso

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

53

43 POSTER Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC)

T. Okusaka, F. Kanai, M. Ikeda, C. Morizane, H. Yoshida, R. Tateishi, S. Shiina, Y. Kondo, K. Tagawa, M. Omata

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

54

44 POSTER The BH4 domain is required for proangiogenic function of bcl-2

D. Del Bufalo, D. Trisciuoglio, M. Desideri, S. Scarpino, L. Ruco, G. Zupi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

55

45 POSTER VEGF targeting increases the cystostatic effect of docetaxel on prostate and breast tumor cells; a new interpretation of the therapeutic effect

G. Pagès, J. Durivault, J.M. Hannoun-Levi, A. Viera, C. Ortholan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

56

46 POSTER VEGF receptor expression in human tumours: VEGFR-2 and -3 are confined predominantly to tumour vasculature

N.R. Smith, D.J. Baker, N.H. James, K.E. Ratcliffe, S.E. Ashton, N. Gray, A.J. Ryan, J.M. Jürgensmeier, C. Womack

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

57

47 POSTER UNBS5162: A new naphthalimide derivative with radiosensitizing and anti-angiogenic activity entering phase I

T. Mijatovic, N. DeNève, C. Bruyère, G. Simon, J. Dewelle, E. Van Quaquebeke, E. Van Der Aar, F. Van Vynckt, F. Lefranc, R. Kiss

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

58

48 POSTER sFLT01, an anti-angiogenic protein with antitumor activity

R. Bagley, M. Yao, L. Kurtzberg, H. Rubin, W. Weber, P. Pechan, W. Brondyk, A. Scaria, J. Kaplan, B. Teicher

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

59

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

J. Spratlin, H.T. Arkenau, S. George, N.J. Serkova, M. Germuska, K. Brock, R. Gedrich, M. Scurr, G.D. Demetri, D.R. Camidge

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

60

50 POSTER Unique enzymatic profile of a potent and selective VEGFR/PDGFR tyrosine kinase inhibitor, TAK-593: potent pseudo-irreversibility against VEGFR and PDGFR

H. Miki, H. Iwata, M. Amamo, S. Imamura, Y. Takagi, A. Hori

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

61

51 POSTER TAK-593, a potent and selective VEGFR/PDGFR tyrosine kinase inhibitor, effects the tumor vascularity and vascular permeability

A. Hori, Y. Kakoi, Y. Takagi, K. Nakamura, S. Tsuchiya

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

62

52 POSTER VEGFR2 targeted antibody and small molecule combinations in renal cell and hepatocellular cancer models

J.R. Tonra, E. Corcoran, I. Duignan, M.J. Plym, J. Schwartz, H. Youssoufian, D. Surguladze, Z. Zhu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

63

53 POSTER Combination treatment of VEGFR inhibitor AV-951 and rapamycin reveals distinct mechanisms of each agent's anti-tumor activity

M. Robinson, J. Lin, H. Yang, X. Sun, V. Ona, K. Kannan, J. Heyer, G. Meng, Y. Zhou, W. Rideout

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

64

54 POSTER Common usage of the GEP100-Arf6-AMAP1 pathway in tumor invasion, angiogenesis and vascular permeability

A. Hashimoto, S. Hashimoto, E. Ogawa, M. Hirose, M. Morishige, T. Menju, M. Shibuya, H. Sabe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

65

55 POSTER Combination therapy of an anti-PDGFRb antibody with an anti-VEGFR2 antibody leads to enhanced antitumor activity

J. Shen, M. Prewett, C. Damoci, H. Zhang, M.D. Vil, H. Li, J. Tonra, Z. Zhu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

66

56 POSTER In vivo profiles of a novel compound, TAK-593, a highly potent and selective inhibitor against VEGFR and PDGFR tyrosine kinases

A. Mizutani, Y. Nagase, K. Nakamura, A. Hori

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

67

57 POSTER Calixarene-based angiogenesis inhibitor 0118 attenuates endothelial cell anergy and promotes a cytotoxic T-cell-mediated anti-tumor response

K. Mayo, R.P.M. Dings, K.B. Vang, A.W. Griffioen, M. Farrar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

68

58 POSTER Novel approaches to breast cancer therapy – simultaneous targeting to tumor and endothelial cells of tumor blood vessels

V. Moura, M.C.P. Lima, S. Simões, J.N. Moreira

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

69

59 POSTER Antiangiogenic and tumor growth inhibitory effects of heparin- taurocholate conjugate

Y. Byun, S.Y. Kim, R.W. Park, E.S. Lee

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

70

60 POSTER Expression of a gastrin transcript in gastrointestinal cancer cells which allows maintenance of expression in hypoxia

A. Grabowska, C. Berry, M. Bushell, A. Willis, S.A. Watson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

71

61 POSTER Contrast enhanced perfusion CT (CEPCT) predicts early response of sunitinib in renal cell carcinoma (RCC) patients

V. Grünwald, N. Hastuerk, M. Fenner, P. Ivanyi, C. Reuter, A. Ganser, M. Galanski, H. Shin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

72

62 POSTER Expression and functional activity of interleukin-8 receptors on human malignant melanoma cells

D. Trisciuoglio, C. Gabellini, G. Zupi, D. Del Bufalo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

73

63 POSTER Response of papillary cell carcinoma to antiangiogenics: a retrospective analysis

J. Medioni, J. Wassermann, V. Molinie, A. Vieillefond, A. Cassar, A. Meajean, S. Oudard

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

74

64 POSTER Neurobehavioral properties of penclomedine (PEN) and derivatives

L.R. Morgan, M.E. Thornton, E.N. Benes, R.F. Struck, A.H. Rodgers, B.S. Jursic, G.J. LaHoste, G. Bastian, R.B. Thompson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

75

65 POSTER Hypoxic conditions increase hypoxia response element and vascular endothelial growth factor promoter reporter activity within the hollow fibre assay in vivo

R. Argent, Y. Yin, A.M. Grabowska, P. Clarke, N. Mann, E. Royal, S.A. Watson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

76

66 POSTER Synergistic anti tumor effect of histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of malignant melanoma

Y. Kato, I. Yoshino, T. Maeda, R. Tsuboi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

77

67 POSTER A relevant panel of human uveal melanoma xenografts directly established from primary and/or metastatic patient's tumor for pharmacological preclinical assays

F. Némati, X. Sastre, J. Couturier, P. Mariani, S. Piperno-Neumann, L. Desjardins, O. Lantz, A. Dahiani, S. Arrufat, M.F. Poupon, D. Decaudin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

78

68 POSTER Sensitivity of a disseminated in vivo model of L363 plasma cell leukaemia against antitumoral compounds sorafenib, bortezomib, and dexamethasone

J. Schueler, D. Wider, M. Wagner, H.H. Fiebig, M. Engelhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

79

69 POSTER Evaluating the duel kinase inhibitor lapatinib: Bioanalytical method development and pharmacokinetic analysis in mouse, rat, and human and determination of in vivo efficacy in a panel of EGFR wildtype and mutant human tumor xenograft models

J. Cooper, F.E. Nieves, J. Kuhn, C.H. Takimoto, A.W. Tolcher, M.J. Wick

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

80

70 POSTER In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response

M. Batey, J.L.R. Brito, H. Maitland, H. Leung, A. Hall, G. Jackson, D.R. Newell, J.A.E. Irving

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

81

71 POSTER Features of chemo and radiotherapy response of a new model of breast cancer xenograft derived from a BRCA2 germ-line mutation carrier patient's tumour

E. Marangoni, L. De Plater, B. Froget, L. Durand, S. Piperno-Neumann, B. Sigal-Zafrani, D. Stoppa-Lyonnet, A. Laugé, D. Decaudin, M.F. Poupon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

82

72 POSTER Preclinical evaluation of the tyrosine kinase inhibitor erlotinib: Bioanalytical method development and pharmacokinetic analysis and in vivo evaluation and comparison in a panel of human EGFR wildtype and mutant tumor xenograft models

F.E. Nieves, J. Cooper, G.L. Mangold, J. Kuhn, C.H. Takimoto, A.W. Tolcher, M.J. Wick

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

83

73 POSTER Establishment of human primary tumor xenograft models in nude mice

C. Liu, Y. Liu, W. Pan, Y. Chen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

84

74 POSTER Experimental therapeutic approach of human diffuse large B-cell lymphoma xenografts by doxycycline, alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab

F. Assayag, N. Brousse, J. Couturier, E. Macintyre, C. Mathiot, L. De Plater, S. Dewulf, A. Vincent-Salomon, M.F. Poupon, D. Decaudin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

85

75 POSTER Establishment, validation, and in vivo evaluation of tumor explant models of adenoid cystic carcinoma: effects of FDA-approved and candidate therapies in human ACC xenografts

F.E. Nieves, C.A. Moskaluk, D. Sidransky, C.H. Takimoto, A.W. Tolcher, J. Kaufman, M.J. Wick

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

86

76 POSTER Imaging the totality of cancer progression in real time

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

87

77 POSTER Prediction and in vivo validation of AZD0530 sensitivity by gene expression profiling in human pancreatic tumor xenografts

N.V. Rajeshkumar, A.C. Tan, J. Wheelhouse, A. Jimeno, W.A. Messersmith, T.P. Green, M. Hidalgo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

88

78 POSTER Tyrosine kinase inhibitors, such as TAK-285, GW572016 or SU11248, protect or damage the heart based on their ability to activate AMPK

S.A. Shell, R.L. Wappel, P. Trusk, Y. Ohta, W. Klohs, S.S. Bacus

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

89

79 POSTER Development of a gene signature predicting response to Cetuximab in human tumor xenograft models

H. Fiebig, J.B. Schüler, T. Metz, T. Beckers, A. Korrat

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

90

80 POSTER Inhibition of MEK1/2 signalling results in decreased levels of intracellular lactate in human melanoma and colorectal cancer cells as observed with magnetic resonance spectroscopy

M. Falck Miniotis, P. Workman, M.O. Leach, M. Beloueche-Babari

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

91

81 POSTER Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met/VEGFR multitargeted kinase inhibitor in Phase I clinical trials

N. Beaulieu, I. Dupont, C. Beaulieu, H. Nguyen, H. Ste-Croix, S. Claridge, L. Isakovic, A. Vaisburg, J.M. Besterman, C. Maroun

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

92

82 POSTER Prevalence of G12R or Q61H K-Ras mutations in pancreas cancer and development of Ras-targeted immunotherapy

A. Franzusoff, Z. Guo, Y. Lu, S. Oakes, A. Britton, V. Fiolkoski, T. King, D. Quick, J. Frenz, D. Apelian

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

93

83 POSTER A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor

V. Novotny-Diermayr, V.M. Nayagam, H.H. Hentze, A.L. Liang, Y.K. Loh, N. Sausgruber, P. Yeo, K. Ethirajulu, J.M. Wood

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

94

84 POSTER Development of predictive markers of responsiveness to the MEK 1/2 Inhibitor AZD6244 in Colorectal Cancer (CRC)

S. Nallapareddy, J.J. Tentler, C.D. Coldren, T.M. Pitts, S.A. Kaufman, S.G. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

95

85 POSTER Pharmacodynamic and efficacy relationship of MLN4924, a novel small molecule inhibitor of Nedd8-activating enzyme, in human xenograft tumors grown in immunocompromised mice

A. Berger, J. Yu, J. Garnsey, M. Milhollen, J. Zhang, T. Traore, L. Tou, A. McDonald, K. Burke, P.G. Smith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

96

86 POSTER Aberrant promoter hypermethylation of DAPK gene is an independent prognostic factor in patients with diffuse large B-cell lymphomas

K. Amara, M. Trimeche, S. Ziadi, L. Laatiri, M. Hachana, S. Korbi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

97

87 POSTER Correlation analysis utilizing measurements of tumor biomarkers and antibody efficacy against EGFR, IGF1R and VEGFR2 receptors in multiple tumor models

D. Deevi, L. Huiling, D.L. Ludwig, Z. Zhenping, L. Witte, J. Tonra

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

98

88 POSTER Development of proximity-based immunoassays for activated HER1, HER2, and HER1-HER2 heterodimers in formalin-fixed, paraffin-embedded (FPPE) cells

L. Defazio-Eli, J. Wallweber, K. Frankson, T. Dao-Pick, T. Dang, R. Dua, L. Goodman, G. Parry, J. Winslow

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

99

89 POSTER Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway

A.D. Laird, A. Sillman, B. Sun, A. Mengistab, F. Chu, M. Lee, B. Cancilla, S.K. Aggarwal, F. Bentzien

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

100

90 POSTER Differential effects of blockade of the HER3-PI3K-Akt pathway by EGFR kinase inhibitors and EGFR monoclonal antibodies on combinations with IGF-1R kinase inhibition

E. Buck, A. Eyzaguirre, D. Epstein, J. Pachter, J. Haley, N. Miglarese, K. Iwata

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

101

91 POSTER Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer (CRC)

T.M. Pitts, S.A. Kaufman, J.J. Tentler, S. Leong, C.D. Coldren, F.R. Hirsch, M. Varella-Garcia, S.G. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

102

92 POSTER Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition

B. Jacobs, R. Van Oirbeek, B. Biesmans, S. Fieuws, W. De Roock, J. De Schutter, Y. Humblet, M. Peeters, E. Van Cutsem, S. Tejpar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

103

93 POSTER Phase I assessment of mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase

A. Chakravarty, V.B. Shinde, K. Galvin, L. Silverman, B. Stringer, H. Danaee, O. Eton, M. Manfredi, J. Ecsedy

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

104

94 POSTER Expression of leptin receptor is an independent prognostic marker of Middle Eastern colorectal carcinomas

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

105

95 POSTER A comparative analysis of megakaryocyte potentiating factor and mesothelin as serum markers for the detection of malignant pleural mesothelioma

K. Iwahori, S. Serada, T. Takahashi, Y. Souma, M. Kim, Y. Kishi, I. Kawase, T. Naka

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

106

96 POSTER Potential importance of the ceramide pathway in the action of the tumour vascular disrupting agent ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid)

B.C. Baguley, Q. Ding, P. Kestell, S. Alix

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

107

97 POSTER Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647

F. Schimmoller, N.A. Rizvi, V.S. Vysotskaia, R.P. Funke, S. Dixon, R.E. Buller

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

108

98 POSTER DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

W. De Roock, M. Janssens, B. Biesmans, B. Jacobs, J. De Schutter, Y. Humblet, M. Peeters, E. Van Cutsem, P. Marynen, S. Tejpar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

109

99 POSTER Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation

R. Wooster, W. Cornwell, J. Jing, J. Greshock, A. Gilmartin, D. Sutton, J. Jackson, S. Laquerre, B. Weber, Y. Degenhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

110

100 POSTER The Expression of c-erb B2 and p53 in human gastric cancer: Correlation to clinicopathologic features and cancer recurrence

H. Hur, W. Kim, H.M. Jeon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

111

101 POSTER Identification of alpha-enolase autoantibody as a novel biomarker in non-small cell lung cancer

S. Serada, P. He, T. Takahashi, K. Iwahori, Y. Souma, A. Kim, T. Naka

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

112

102 POSTER Quantitative clinical biomarker measurement using multiplexed quantum dot immunhistochemistry

E. Sweeney, T.H. Ward, N. Gray, C. Womack, G. Jayson, A. Hughes, C. Dive, R. Byers

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

113

103 POSTER Development of highly quantitative, sensitive, and reproducible immunoassays for the detection of EGFR/HER1 and ErbB3/HER3 in formalin-fixed, paraffin-embedded (FFPE) tumor tissue

Y. Shi, A. Mukherjee, J. Weston, J. Bose, X. Nguyen, A. Paquet, C. Chappey, G. Parry, L. Goodman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

114

104 POSTER Role of P21 in sensitivity to DACH-platinum compounds, oxaliplatin and ProLindac, in human cancer cells

M. Serova, I. Bieche, M. Broggini, E. Erba, A. Ghoul, M. D'Incalci, E. Cvitkovic, D. Nowotnik, S. Faivre, E. Raymond

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

115

105 POSTER Evaluation of PET tracer uptake in mouse xenograft models of hormone-dependent prostate cancer

D. Kukuk, G. Reischl, O. Raguin, S. Wiehr, F. Cay, D. Bukala, O. Duchamp, J.M. Judenhofer, H.J. Machulla, B. Pichler

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

116

106 POSTER −765G>C COX2 polymorphism and bladder cancer onset: implications for chemoprevention in a Portuguese population

A. Pereira, L. Lima, S. Magalhães, L. Santos, R. Medeiros

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

117

107 POSTER Novel epitopes presented by the HLA-A*0201 are recognized by the cytotoxic T lymphocytes of breast cancer survivors

O. Hawkins, R. VanGundy, A. Eckerd, W. Bardet, R. Buchli, J. Weidanz, W. Hildebrand

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

118

108 POSTER Screening Plasma Thioredoxin-1 (Trx-1) to potentially guide clinical development of the Trx-1 Inhibitor PX-12

D.L. Kirkpatrick, A. Hiscox, M. Boice, D. Swanlund, L. Baronic, L. Pestano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

119

109 POSTER Promoter hypermethylation of the NORE1A occurs in endometrial cancer

H. Chung, J. Kim, N. Park, Y. Song, S. Kang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

120

110 POSTER TM9SF2, a novel cell surface potential target in breast cancer

S. Abou-Sharieha, Y. Sugii, H. Tada, M. Seno

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

121

111 POSTER Design of a screening procedure to select patients with leukemia for treatment with F 14512, a novel targeted cytotoxic agent

J.M. Barret, J.P. Annereau, V. Brel, M. Broussas, Y. Guminski, T. Imbert, C. Dumontet, L. Goetsch, N. Guilbaud, C. Bailly

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

122

112 POSTER A clinical chemistry approach for identifying biomarkers as surrogate endpoints in therapy directed against chemokine mediated metastasis

P. Moretto, S.J. Hotte, H.W. Hirte, A. Iacobucci, K. Evans, D. Wong, W. Korz, P.A. Kavsak

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

123

113 POSTER The RhoA kinase (ROCK) inhibitor Y27632 and specific novel structural analogues of this compound cause irreversible elimination of transformed NIH3T3 cells from cultures

L. Hampson, X.T. He, A.W. Oliver, J. Hadfield, T. Kemp, A. McGown, J. Butler, H.C. Kitchener, I.N. Hampson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

124

114 POSTER Ursodeoxycholic acid decreases proliferation of normal intestinal epithelial cells in vivo and in vitro

S. Subramanian, C. Loddenkemper, M.L. Hanski, M. Zeitz, C. Hanski

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

125

115 POSTER Effects of MMR status on colon carcinoma cell survival after 5-FU treatment in vitro and in vivo

B. Choudhary, M.L. Hanski, M. Bhonde, M. Zeitz, C. Hanski

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

126

116 POSTER Effective combination of green tea EGCG and EGFR-TKI erlotinib for chemoprevention and therapy in head and neck cancer

D.M. Shin, A.R.M. Amin, X. Zhang, Z.G. Chen, F.R. Khuri

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

127

117 POSTER ANG1005, Paclitaxel conjugated to the angiopep brain transport vector for the treatment of brain cancer: preclinical studies

R. Gabathuler, M. Demeule, A. Regina, C. Che, F. Thomas, A. Abulrob, Q.R. Smith, D. Stanimirovic, R. Beliveau, J.P. Castaigne

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

128

118 POSTER Comparative pharmacokinetic study of abiraterone acetate in a capsule and tablet formulation

F.I. Raynaud, V. Martins, T. Yap, C. Carden, R.L. Jones, S.B. Riggs, F.F. Kabbinavar, D. McIntosh, G. Lee, J.S. De Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

129

119 POSTER The effects of treatment sequencing on the antitumor activity of vandetanib and paclitaxel in a model of ovarian carcinoma xenograft

M. Cesca, R. Frapolli, S. Scarlato, A.J. Ryan, E. Bello, R. Giavazzi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

130

120 POSTER Customized PEG linkers improve tumor delivery of RNA antagonist oligonucleotides

H. Zhao, P. Sapra, P. Reddy, R. Bandaru, M. Wang, P. Zhu, M. Mehlig, P. Kraft, L.M. Greenberger, I.D. Horak

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

131

121 POSTER Novel customized releasable polyethylene glycol (PEG) linkers improve tumor delivery and efficacy of locked nucleic acids oligonucleotides

P. Sapra, H. Zhao, P. Reddy, M. Wang, R. Bhandaru, J. Malaby, P. Kraft, M. Mehlig, L.M. Greenberger, I.D. Horak

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

132

122 POSTER In silico modelling of doxorubicin penetration through multicell layers

R. Phillips, P. Loadman, P. Jones, S. Smye, C. Twelves, B. Sleeman, C. Evans

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

133

123 POSTER Potent synergy of dual anti-tumor peptides for growth suppression of human glioblastomas using highly efficient peptide-delivery system

E. Kondo, T. Yoshino

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

134

124 POSTER Nanoparticles as drug delivery device in cancer therapy: investigation of nanodiamond internalization and cellular effects in endothelial and glioblastoma cells

A. Pagano, S. Honoré, V. Joshi, A. Barbier, M. Sennour, A. Thorel, A. Krueger, P. Curmi, D. Braguer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

135

125 POSTER The antineoplastic activities of a novel oral formulation of interleukin-2 (IL-2)

S. Ko, S. Zhang, R. Qu, X. Chen, M. Sullivan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

136

126 POSTER Novel phage display-derived peptides for tumor- and vascular- targeted therapies against neuroblastoma

F. Pastorino, S. Marchiò, D. Di Paolo, M. Loi, A. Corti, F. Bussolino, D. Ribatti, W. Arap, R. Pasqualini, M. Ponzoni

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

137

127 POSTER Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK)

C. Cano, N.J. Curtin, B.T. Golding, K. Haggerty, I.R. Hardcastle, M. Hummersone, K. Menear, C. Richardson, G.C.M. Smith, R.J. Griffin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

138

128 POSTER Unraveling therapeutic bio-signatures through pathway mapping at the single cell level using an analysis platform for simplified interrogation of complex data sets

A. Cappione, L. Zieske, R. Lefebvre, D. King

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

139

129 POSTER Design, synthesis and evaluation of bivalent conformationally constrained Smac mimetics as a new class of anticancer agents

H. Sun, J. Lu, L. Bai, Z. Nikolovska-Coleska, C. Yang, S. Qiu, X. Ling, M. Guo, D. Yang, S. Wang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

140

130 POSTER Structure–activity relationships for a library of C2-aryl substituted monomeric pyrrolo[2,1-c][1,4]benzodiazepines (PBD) antitumour agents

M. Coffils, D.I. Jodrell, S.M. Guichard, J.A. Hartley, P.W. Howard, D. Antonow, D.E. Thurston

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

141

131 POSTER Specific induction of the p53 pathways by low dose cytotoxic drugs assessed by gene expression pattern analysis

M.L. Choong, P.Z.K. Kwek, H. Yang, M.A. Lee, D.P. Lane

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

142

132 POSTER SRJ09, a lead compound in anticancer drug design: in vitro, in vivo and mechanistic studies

J. Stanslas, S.H. Lim, S.R. Jada, S.R. Sagineedu, N.H. Lajis, M.F. Stevens

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

143

133 POSTER Discovery of potent and selective focal adhesion kinase inhibitors

E. Kawahara, T. Miyake, N. Matsuura, I. Umemura, K. Masuya, T. Kanazawa, T. Meyer, J. Mestan, S. Hatakeyama, O. Ohmori

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

144

134 POSTER The rational design of inhibitors of the telomere-hnRNP A1 interaction

X. Billot, R. Marcellus, L. Belec, J.F. Trempe, N. Safaee, K. Gehring, J. Schrag, M. Cygler, M. Lawless, P. Beauparlant

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 105 KB

english, 2008

145

135 POSTER Design and synthesis of BCA2 inhibitors

G. Brahemi, A. Fiasella, A. Brancale, A. Westwell, A. Burger

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 86 KB

english, 2008

146

136 POSTER Discovery of SB939, an HDAC inhibitor with a superior preclinical profile

H. Wang, N. Yu, D. Chen, E.T. Sun, K. Sangthongpitag, Z. Bonday, P. Yeo, E. Kantharaj, J.M. Wood, B.W. Dymock

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 86 KB

english, 2008

147

137 POSTER Characterization of GSK1120212 a novel allosteric inhibitor of MEK1/2

S. Erskine, C. Rominger, F. Zappacosta, S. Laquerre, J. Adams, P. Tummino, Z. Lai

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 103 KB

english, 2008

148

138 POSTER Design, synthesis, biochemical and biological evaluations of novel and potent small-molecule inhibitors of STAT3

J. Chen, L. Bai, Z. Nikolovska-Coleska, J. Zhang, C. Gomez, H. Yi, K. Krajewski, S. Jiang, P. Roller, S. Wang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

149

139 POSTER Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate

F. Bichat, M. Demeule, B. Lawrence, O. Raguin, B. Sourzat, R. Gabathuler, J. P. Castaigne, P. Genne

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

150

140 POSTER Macrolactone based inhibitors of Heat Shock Protein 90

J.E.H. Day, C.J.M. Moody, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

151

141 POSTER Design and synthesis of novel indole derivatives as selective apoptosis-inducers

N.I. Ziedan, A.D. Westwell, S. Fogli

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 88 KB

english, 2008

152

142 POSTER Interaction of chlorambucil and intercalating aniline mustards with defined DNA sequences using MALDI and ESI mass spectrometry

A.M.S. Abdul Majid, G. Smythe, W.A. Denny, L.P.G. Wakelin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

153

143 POSTER Ex-vivo plasma protein binding and in vitro evaluation of AP5346 (ProLindac TM; PL), a novel polymer-bound platinum: Evidence showing that >72 h DACH-platinum (Pt) release may play a major role in cytotoxicity

K. Rezai, M. Serova, E. Raymond, S. Faivre, F. Bourdel, E. Cvitkovic, S. Weill, S. Urien, F. Lokiec

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

154

144 POSTER XL888, a novel, synthetic, orally bioavailable inhibitor of Hsp90

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 127 KB

english, 2008

155

145 POSTER Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer

P.A. Clarke, L. Welsh, M. Valenti, S. Eccles, P. Workman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 98 KB

english, 2008

156

146 POSTER CU-0305, a novel synthetic Hsp90 inhibitor with unique pharmacology properties

R. Boa, C. Lai, H. Qu, D. Wang, L. Yin, X. Cai, H. Zhai, G. Xu, X. Tao, B. Zifcak, C. Qian

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 98 KB

english, 2008

157

147 POSTER AT13387, a fragment derived clinical candidate is active in lung and melanoma models

J. Lyons, B. Graham, J. Curry, M. Reule, T. Smyth, L. Fazal, B. Williams, M. Yule, M. Squires, N. Thompson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 98 KB

english, 2008

158

148 POSTER Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors

C. Fritz, B. Tillotson, J. Ge, E. Normant, K. Depew, J. Basuki, N. Hafeez, J. Patterson, J.R. Porter, V. Palombella

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

159

149 POSTER Acetylation of molecular chaperones by histone deactylase inhibitors (HDACI)

K. Reynald, M. Rowlands, A. Hardcastle, L. Stimson, A. Bannister, P. Workman, W. Aherne

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

160

150 POSTER MPC-3100: A non-natural product Hsp90 inhibitor with anti-tumor activity in pre-clinical models

D. Wettstein, V. Baichwal, D. Papac, D. Cimbora, R. McKinnon, A. Bajji, S.H. Kim, R. Tangallapally, B. Markovitz, R. Trovato

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

161

151 POSTER Efficacy of panobinostat (LBH589) in lung cancer: potent anticancer activity in both in vitro and in vivo tumor models

P. Atadja, W. Shao, Y. Wang, J. Growney, Y. Feng, Y.M. Yao, A. Wallace, C. Crisanti, S. Fawell, S. Albelda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

162

152 POSTER Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat

Z. Zhong, J. Simmons, P. Timmermans

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

163

153 POSTER IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class

J. Lee, L. Grenier, E. Holson, K. Slocum, J. Ge, E. Normant, J. Hoyt, J. Cushing, J. Sydor, J. Wright

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

164

154 POSTER Hsp90 is expressed and represents a novel target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxy- geldanamycin

X. Wu, P. Wardega, L. Gedda, A. Wanders, S. Bergström, L. Sooman, J. Gullbo, M. Bergqvist, J. Lennartsson, S. Ekman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

165

155 POSTER Pharmakokinetic/phamacodynamic relationship in human xenograft models and PBMC's treated with the Hsp90 inhibitor NVP-AUY922

M.R. Jensen, S. Ide, J. Brueggen, J. Schoepfer, M. Motwani, X. Wang, T. Radimerski, C. Quadt, C. Garcia-Echeverria, P. Chene

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

166

156 POSTER BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows potent anti-tumor activity as a single agent and in combination with standard of care therapies in preclinical tumor models

K. Lundgren, N. Timple, G. Ibanez, C. Yang, L. Neely, A. Kamal, K. Hong, H. Zhang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

167

157 POSTER BMS-641988: A highly potent and rationally designed inhibitor of the androgen receptor (AR), with efficacy in castration resistant human prostate cancer xenograft models

M. Salvati, R.M. Attar, A. Balog, J. Dell-John, M. Jure-Kunkel, S. Krystek, M. Obermeier, T.J.R. Spires, G. Vite, M. Gottardis

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

168

158 POSTER Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy- naive and docetaxel treated castration-resistant prostate cancer (CRPC)

G. Attard, A. Reid, N. Babu Oommen, L. Folkerd, D. Olmos, E. Thompson, G. Maier, M. Dowsett, D. Dearnaley, J.S. De Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

169

159 POSTER Re-inducing sensitivity to abiraterone acetate, a novel CYP17 inhibitor with a high level of anti-tumour activity in castration resistant prostrate cancer

N. Oommen, G. Attard, A. Reid, L. Folkerd, P. Fong, J. Hunt, M. Dowsett, D. Dearnaley, C. Parker, J. De-Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

170

160 POSTER Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials Consortium

H. Scher, T. Beer, C. Higano, C. Logothetis, J. Shelkey, D. Hung, M. Hirmand, S. Larson, M. Fleisher, C. Sawyers

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

171

161 POSTER Potent anticancer activity of panobinostat (LBH589) in models of hormone-refractory prostate cancer (HRPC): targeting the androgen receptor

W. Shao, J. Growney, G. O'Connor, Y. Feng, H. Scher, Y.M. Yao, S. Fawell, P. Atadja

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

172

162 POSTER Effects of SOD2 silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer

N. Sharifi, E.M. Hurt, S. Thomas, W.L. Farrar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

173

163 POSTER The steroid sulfatase inhibitor BN83495 inhibits E1S-stimulated growth of DMBA-induced mammary tumour in rat

Z. Koob, M. Hillairet de Boisferon, F. Bichat, E. Bascompta, A. Perez, B. Potter, M. Reed, T. Ali, G.P. Prevost

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

174

164 POSTER Inhibition of CXCR-4 reduces breast cancer xenograft metastasis to multiple organs

M.M. Richert, D. Wong, W. Korz, D.R. Welch

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

175

165 POSTER Novel therapeutic efficacy of E7080 for controlling experimental metastases of human lung cancer cells in natural killer cell-depleted severe combined immunodeficient mice

M. Hanibuchi, H. Ogino, K. Ikuta, S. Kakiuchi, H. Uehara, A. Tsuruoka, T. Uenaka, Y. Nishioka, S. Yano, S. Sone

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

176

166 POSTER Inhibitors of mitochondrial ATP synthesis show preferential cytotoxicity to pancreatic cancer cells under glucose-deprived conditions

I. Momose, D. Tatsuda, M. Kawada, D. Ikeda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

177

167 POSTER The EGFR-GEP100-Arf6 pathway in breast cancer invasion and metastasis

S. Hashimoto, M. Morishige, E. Ogawa, Y. Toda, H. Kotani, M. Hirose, A. Hashimoto, Y. Nio, H. Wada, H. Sabe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

178

168 POSTER Endothelin A receptor/beta-arrestin signaling is critical for ovarian cancer metastasis: novel molecular therapeutic applications

L. Rosanò, R. Cianfrocca, S. Masi, F. Spinella, V. Di Castro, A. Biroccio, E. Salvati, R. Nicotra, P.G. Natali, A. Bagnato

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

179

169 POSTER PI3K/Akt pathway regulates Shh/Gli-mediated EMT and invasion of gastric cancer cells

M.H. Kang, H.N. Kang, J.L. Kim, J.S. Kim, Y.A. Yoo, S.C. Oh

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

180

170 POSTER PI3K/Akt pathway regulates BMP2-mediated EMT and invasion of gastric cancer cells

J.L. Kim, M.H. Kang, H.N. Kang, J.S. Kim, S.C. Oh, Y.A. Yoo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

181

171 POSTER Integrin LFA-1 expression regulates angiogenesis-stimulating potential of colorectal carcinoma cells at premetastatic niches in the liver

M. Valcárcel, A. Jaureguibeitia, C. Salado, A. Lopategi, B. Arteta, F. Muruzabal, L. Mendoza, F. Vidal-Vanaclocha

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

182

172 POSTER Tumor-induced liver nerve growth factor (NGF): a new target for stromal cell inhibition during metastatic colorectal carcinoma growth

F. Basaldua, A. Lopategi, B. Arteta, A. Valdivieso, J. Ortiz de Urbina, F. Vidal-Vanaclocha

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

183

173 POSTER Arf6-AMAP1 pathway in invasion of lung cancer and malignant mesothelioma cell lines

T. Menju, S. Hashimoto, A. Hashimoto, E. Ogawa, H. Wada, H. Date, H. Sabe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

184

174 POSTER Epigenetic changes of tumor suppressor genes and therapeutic implications in glioblastoma

L. Sooman, J. Gullbo, J. Lennartsson, S. Bergström, E. Blomquist, M. Bergqvist, S. Ekman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

185

175 POSTER Role of ERK activation in triptolide-induced apoptosis in MDA-MB-231 human breast cancer cells

B.J. Tan, G.N. Chiu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

186

176 POSTER Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors

P. Schöffski, V. Grünwald, G. Giaccone, R. Salazar, M. Majem, H. Dumez, E. Casado, B. de las Heras, J.P. Armand

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

187

177 POSTER Antiproliferative effects of fluoro-chalcone derivatives in human melanoma A375 cells and peripheral blood mononuclear cells

K. Henmi, Y. Hiwatashi, N. Toyama, T. Hirano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

188

178 POSTER Eph receptor A2 modulation in human glioma cell lines by the natural product, Schweinfurthin A

A. Monks, T. Turbyville, E.D. Harris, B. Kaas, J.A. Beutler

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

189

179 POSTER Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma

J.C. Soria, R. Plummer, A. Soto, C. Massard, H. Calvert, R. Prados, E. Angevin, C. Jones, B. de las Heras

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

190

180 POSTER The novel taxane derivative, IDN6140, crosses the Blood Brain Barrier and has a promising activity in CNS tumors

E. Marangon, F. Sala, R. Frapolli, C. Manzotti, P. Morazzoni, G. Pratesi, G. Petrangolini, M. Tortoreto, M. D'Incalci, M. Zucchetti

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

191

181 POSTER Evaluation of the marine compound PM02734 against a pediatric tumor cell line panel by ITCC preclinical drug evaluation program

B. Geoerger, C. Lanvers, A. Verschuu, P. Aviles, C. Cuevas, J. Boos, G. Vassal, H. Caron

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 85 KB

english, 2008

192

182 POSTER In vitro and in vivo antitumor activity of novel aureolic acid analogues generated by metabolic engineering of the biosynthetic pathways in Streptomyces argillaceus and treptomyces griseus subsp. griseus

A. Malek, L.E. Núñez, N. Menéndez, F. Morís, G.M. Carbone, J. Rohr, C. Méndez, J.A. Salas, C.V. Catapano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

193

183 POSTER New clerodane diterpenes from Casearia capitellata as potential antitumour agents

J. Stanslas, G. Bagalkotkar, S.C. Tang, A.S. Hamzah, K. Shaari, N.H. Lajis, M.S. Saad

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

194

184 POSTER New antitumour agents from Phyllanthus pulcher, a tropical medicinal plant

J. Stanslas, G. Bagalkotkar, S.C. Tang, A.S. Hamzah, K. Shaari, N.H. Lajis, M.S. Saad

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 84 KB

english, 2008

195

185 POSTER Chlamydocin, a HDAC inhibitor identified by Compare analyses in a cellular screen

H.H. Fiebig, T. Metz, T. Beckers, A. Korrat, G. Kelter

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

196

186 POSTER Screening for the inhibitor against filopodia protrusion

M. Kitagawa, E. Tashiro, T. Soga, M. Imoto

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

197

187 POSTER Fusicoccin derivative (ISIR-005) suppresses anchorage-independent growth of cancer cells through anoikis activation

Y. Honma, M. Akimoto, T. Sassa, N. Kato

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

198

188 POSTER Leucinostatins suppress prostate cancer cell growth through the tumour-stromal cell interactions

M. Kawada, H. Inoue, I. Momose, T. Masuda, D. IKeda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 78 KB

english, 2008

199

189 POSTER Solution structure of a 2:1 C2-(2-naphthyl)pyrrolo[2,1-c][1,4]- benzodiazepine (PBD) DNA adduct: molecular basis for unexpectedly high DNA helix stabilization

D. Antonow, T. Barata, T.C. Jenkins, G.N. Parkinson, P.W. Howard, M. Zloh, D.E. Thurston

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

200

190 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of rapamycin combined with cytotoxic drugs used frequently in treatment of childhood cancer

P.J. Houghton, C.L. Morton, J.M. Maris, S.T. Keir, R.B. Lock, H. Carol, R. Gorlick, E.A. Kolb, M.H. Kang, M.A. Smith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

201

191 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the oncolytic picornavirus, NTX-010 (SVV-001)

C.L. Morton, P.J. Houghton, J.M. Maris, R. Gorlick, E.A. Kolb, M.H. Kang, C.P. Reynolds, M.A. Smith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 66 KB

english, 2008

202

192 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419

R. Lock, H. Carol, P. Houghton, C. Morton, D. Phelps, C. Tucker, D. Payne-Turner, C. Zuany-Amorim, M. Smith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 121 KB

english, 2008

203

193 POSTER Preclinical evaluation of the marine compound PM00104 within the ITCC pediatric tumor cell line panel in vitro and in vivo

A. Verschuur, C. Lanvers, B. Geoerger, P. Aviles, P. Rodier, C. Cuevas, J. Boos, G. Vassal, H. Caron

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 121 KB

english, 2008

204

194 POSTER How to prescribe standard chemotherapy or targeted-therapy using a fully featured relational database

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 136 KB

english, 2008

205

195 POSTER Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies

A. Rinaldi, I. Kwee, F. Bertoni, L. Viganò, D. Hess, N. Coceani, C. Sessa, V.M. Rivera, C.L. Bedrosian, C.V. Catapano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

206

196 POSTER Intron 1 CA repeat polymorphism is associated with the sensitivity to EGFR TKIs in NSCLC patients with wild type EGFR

J.Y. Shin, J.O. Kim, S.J. Lim, H.S. Won, T.H. Kim, C.H. Lee, M.S. Kim, J.H. Kang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

207

197 POSTER Pathway determinants of 5-fluorouracil activity

W.L. Tan, D.F. Dong, L.S. Wong, R.A. Soo, I. Fichtner, R. Soong

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

208

198 POSTER Genetic polymorphisms associated with adverse events in childhood acute lymphoblastic leukaemia treated with SHOP-2005 protocol

E. Lopez, I. Martin-Guerrero, J. Ballesteros, M.A. Piñán, A. Navajas, A. Garcia-Orad

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

209

199 POSTER Influence of PXR haplotype variants on paclitaxel pharmacokinetics and pharmacodynamics in Asian cancer patients

B. Chowbay, E. Sandanaraj, S. Lal, Z.P. Wang, T. Kulkarni, W.T. Lim, C.S. Ang Peter, E.H. Tan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

210

200 POSTER Transcriptome analysis method for in vivo mechanism of action study: IMC-D11 anti-FGFR3 +/− cisplatin in bladder cancer models

W. Wang, Y. Cheng, D. Deevi, H. Li, M. Prewett, R. Bassi, M. Malabunga, K. Paz, H. Sun, J. Tonra

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

211

201 POSTER In Mdm2 SNP309 cancer cells the small molecules nutlin-3 and MI-63 facilitate recruitment of RNA polymerase II to p53 target genes

J. Bargonetti, A. Polotskaia, S. Wang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 80 KB

english, 2008

212

202 POSTER Predicting a metastatic treatment response in advanced colorectal cancer patients by gene expression profiling

M. Del Rio, C. Bascoul-Mollevi, F. Bibeau, P. Chalbos, A. Kramar, C. Gongora, M. Ychou, P. Martineau

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

213

203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

B. Besse, K.D. Eaton, J.C. Soria, T.J. Lynch, V. Miller, K.K. Wong, C. Powell, S. Quinn, C. Zacharchuk, L.V. Sequist

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

214

204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study

T.W. Flaig, B.D. Curti, M.S. Gordon, P.J. Van Veldhuizen, W.H. Miller, M.S. Ernstoff, S. Bhatia, N.H. Hunder, N. Royer, J.A. Thompson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

215

205 POSTER A phase II study of oral enzastaurin HCl in patients with metastatic colorectal cancer

B. Glimelius, M. Lahn, S. Gawande, L. Musib, Y. Liu, K.L. Spindler, C. Qvortrup, P. Pfeiffer, A. Jakobsen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

216

206 POSTER Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC)

S.J. Hotte, E.X. Chen, H.W. Hirte, P. Moretto, S. Turner, S.F. Chin, L. Wang, K. MacAlpine, L.L. Siu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

217

207 POSTER Phase II study of gefitinib in combination with cisplatin and concurrent radiotherapy in patients with stage III/IV squamous cell head and neck cancer and to analyse the effect of gefitinib on tumour gene expression

E.H. Tan, C. Goh, A. Loy, S.S. Leong, W.T. Lim, C.K. Toh, T. Tan, J. Wee, K.W. Fong, K.M. Hui

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 97 KB

english, 2008

218

208 POSTER A phase II study of sunitinib, an oral multi-targeted tyrosine kinase inhibitor, in patients with unresectable, locally advanced or metastatic cervical carcinoma: IND184

H. Mackay, A. Tinker, E. Winquist, G. Thomas, J. Sederias, P. Ivy, E.A. Eisenhauer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

219

209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer

G. MacVicar, F.A. Greco, J. Reeves, B. Curti, B. Poiesz, B. Somer, K. Brill, L. Leopold

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

220

210 POSTER Preliminary results of a Phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing first-line therapy for colorectal cancer (CRC)

R. Earhart, S.V. Cheporov, O.A. Gladkov, M.Y. Biakhov, G.S. Baker, H.B. Breitz

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

221

211 POSTER Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)

R. DeJager, L. Roman, N. Lopatkin, P. Karlov, H.B. Breitz, R. Earhart

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

222

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

A.J. Wagner, S. Yazji, J.A. Morgan, E. Choy, S. George, M. Hohos, M. O'Mara, G.D. Demetri

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

223

213 POSTER Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder

J. Barriuso, G. Daugaard, S. Frentzas, L. Fuglsang, R. Glasspool, A. Krarup-Hansen, R.J. Jones, U. Lassen, L. Sengeløv, J.S. De Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

224

214 POSTER AP5346 (ProLindacTM), a pH-dependent polymer-vectorized DACH platinum, is active in borderline potentially platinum-sensitive ovarian cancer (OC) patients: results from an ongoing Phase I/II trial

F. Joly, A. Madroszyk, A. Floquet, D. Gedouin, F. Bourdel, M. Campone

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

225

215 POSTER Prospective study of erlotinib comparing chemotherapy-naive non-small cell lung cancer patients having an activating mutatation in EGFR gene with those having wild-type EGFR gene

D.H. Lee, H.J. Song, Y.M. Lee, Y.H. Choi, S.W. Kim, C. Suh, J.S. Lee

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

226

216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors

B. Markman, P.M. LoRusso, A. Patnaik, E. Heath, A.D. Laird, B. van Leeuwen, K.P. Papadopoulos, J. Baselga

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

227

217 POSTER Pre-clinical evaluation of efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor

S. Patel, D. Sampath, M. Belvin, A. Brown, K. Edgar, L. Lensun, P. Moore, L. Salphati, H. Stern, L. Friedman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

228

218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors

E. Calvo, G. Edelman, J. Baselga, E. Kwak, C. Scheffold, L. Nguyen, G.I. Shapiro

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

229

219 POSTER NVP-BEZ235, a dual pan-PI3K/mTOR kinase inhibitor, is effective in human lung cancer models harboring EGFR mutations

C.R. Schnell, J. Vaxelaire, M. Vogelsanger, M. Hattenberger, F. Stauffer, S. Arnal, C. Garcia-Echeverria, S.M. Maira

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

230

220 POSTER Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo

D. Sampath, M. Belvin, J. Guan, K. Edgar, J. Wallin, W.W. Prior, R. Kassees, P. Moore, S. Patel, L. Friedman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

231

221 POSTER A novel inhibitor of phosphoinositide 3-kinase for the treatment of cancer

K.R. Auger, L. Luo, S. Knight, G. Van Aller, P.J. Tummino, R.A. Copeland, M. Diamond, D. Sutton, J.R. Jackson, D. Dhanak

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

232

222 POSTER RNAi screen for Akt regulator

B.T. Chua, A. Ullrich, D. Gallego-Ortega, A. Ramirez de Molina, J.C. Lacal, J. Downward

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

233

223 POSTER Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation

P. LoRusso, D. Sarker, D. Von Hoff, R. Tibes, M.K. Derynck, J.A. Ware, Y. Yan, G.D. Demetri, J.S. de Bono, A.J. Wagner

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

234

224 POSTER Assessment of the antitumor activity of NVP-BEZ235 in experimental renal cell carcinoma models

M. Michel, J. Vaxelaire, M. Hattenberger, M. Vogelsanger, F. Stauffer, A. Theuer, C. Stephan, M. Ito, C. Garcia-Eccheverria

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

235

225 POSTER Evaluation of antitumor activity of a novel PI3K inhibitor ZSTK474 by various human cancer xenograft models

T. Yamori, M. Okamura

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

236

226 POSTER Anti-angiogenic activity of a novel PI3K inhibitor, ZSTK474

D. Kong, H. Yoshimi, T. Yamori

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

237

227 POSTER Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors

L. Friedman, M. Belvin, J. Le Couter, K. Lin, L. Robillard, D. Sampath, H. Stern, U. Vijapurkar, W. Ye, G. Plowman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

238

228 POSTER Identification and evaluation of PI3 Kinase as new molecular target in neuroblastoma that critically regulates apoptosis resistance

D. Opel, A. Bender, D. Bertele, M. Schneider, C. Poremba, T. Simon, K.M. Debatin, S. Fulda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

239

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

N. Alami, Y. Sun, P. De, D.L. Durden, B. Leyland-Jones

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

240

230 POSTER PI3 Kinase inhibitors broadly sensitize glioblastoma cells for death receptor- or chemotherapy-induced apoptosis

D. Opel, A. Westhoff, A. Bender, V. Braun, K.M. Debatin, S. Fulda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

241

231 POSTER Profiling of cancer cell signaling pathways activated by a novel proteasome inhibitor class (syrbactins) in human neuroblastoma

A. Bachmann, C. Archer, B. Schellenberg, R. Dudler

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

242

232 POSTER Combined therapeutic effects of bortezomib and fenretinide on Neuroblastoma cell growth, apoptosis, and angiogenesis

D. Di Paolo, R. Carosio, F. Pastorino, A. Pezzolo, L.J.V. Galietta, M. Cilli, D. Ribatti, M. Ponzoni, G. Pagnan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

243

233 POSTER Bortezomib and Flavopiridol combination induces down regulation of Mcl-1, mitochondrial permeabilization and cell death in ALCL cells

E. Zorzi, P. Bonvini, L. Mussolin, G. Basso, A. Rosolen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

244

234 POSTER NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors

R. Kurzrock, P. Hamlin, M. Gordon, D. Hong, S. Fu, A. Younes, A. Hannah, M.A. Palladino, M.A. Spear, C. Aghajanian

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

245

235 POSTER Preclinical and clinical monitoring of cell-and circulating plasma specific proteasome biomarkers after treatment with the proteasome inhibitor, NPI-0052

M.A. Palladino, T. Chao, S.T.C. Neuteboom, M. Spear, W. Ma, M. Albitar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

246

236 POSTER Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D cohort

A. Townsend, P. Padrik, P. Mainwaring, T. Price, L. Catley, A. Longenecker, M.A. Palladino, G.K. Lloyd, M.A. Spear, M. Millward

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

247

237 POSTER Leaving groups prolong the duration of 20S proteasome inhibition and enhance the inhibition profile of salinosporamides

B. Potts, R. Manam, V. Macherla, T. Chao, J. Weiss, M. Groll, K. McArthur, S. Neuteboom, M. Palladino, G.K. Lloyd

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

248

238 POSTER The selective proteasome inhibitor carfilzomib in combination with chemotherapeutic agents improves anti-tumor response in solid tumor xenograft models

M. Dajee, M. Aujay, S. Demo, J. Jiang, C. Kirk, S. Lee, F. Parlati, J. Sheilds, M. Sun, E. Suzuki

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 49 KB

english, 2008

249

239 INVITED Oncogenes and tumor suppressor genes control autophagy

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

250

240 INVITED Role of autophagy in cancer resistance

S. Kondo, T. Yokoyama, N. Shinojima, T. Shingu, O. Bogler, Y. Kondo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

251

241 INVITED Novel therapeutic targets within the autophagic pathway

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

252

242 INVITED Targeting apoptosis-resistant cancer cells through autophagic cell death

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

253

243 INVITED Aurora kinase inhibitors: more than one opportunity?

B. Laffranchi, J. Moll, S. Comis

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

254

244 INVITED Polo-like kinase inhibition in oncology: from bench to bedside

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

255

245 INVITED PARP inhibitors in cancer treatment

H. Calvert, E.R. Plummer, N.J. Curtin, R. Edmondson, Y. Drew

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

256

246 INVITED Targeting Her: Can resistance to EGFR inhibitors be overcome?

B. Burtness, L. Weiner, I. Astsaturov, E. Golemis

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

257

1LB Late Breaking First-in-Human study of the First-in-Class Hdm2 inhibitor JNJ-26854165

J. Tabernero, P. Schöffski, L. Dirix, J. Capdevila, H. Dumez, S. Kraljevic, K. Bol, H. Winkler, L. de Bie, B. Rooney, J. Arts, E. Leo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

258

2LB Late Breaking A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole

C. Ryan, A. Harzstark, L. Fong, A. Lin, C. Kilian, A. Molina, E.J. Small

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

259

247 ORAL BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer

F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore Bianchi, S. Arena, P. Saletti, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

260

248 ORAL Notch pathway: a potential new target for the treatment of paediatric ependymomas

C. Dantas-Barbosa, B. Geoerger, S. Puget, L. Lacroix, F. Andreiuolo, A. Valent, P. Varlet, C. Sainte-Rose, G. Vassal, J. Grill

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 78 KB

english, 2008

261

249 ORAL Specific activation of microRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic response in chronic lymphocytic leukemia

D. Sampath, G.A. Calin, V. Puduvalli, G. Gopisetty, C. Taccioli, C.G. Liu, B. Ewald, C. Liu, M.J. Keating, W. Plunkett

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

262

250 ORAL OXA-01, a novel potent mTORC1/TORC2 kinase inhibitor, demonstrates broad spectrum antitumor activity in preclinical models of human cancer

P.C. Gokhale, S.V. Bhagwat, A.P. Crew, A. Cooke, C. Mantis, J.E. Workman, D. Landfair, M. Bittner, J.A. Pachter, R. Wild

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

263

251 INVITED An approach for targeting protein–protein interactions

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

264

252 INVITED Targeting the protein translation factor eIF4E for cancer therapy

J. Graff, B. Konicek, J. Carter, E. Marcusson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

265

253 INVITED Exploring translation initiation as a therapeutic target

J. Pelletier, L. Lindqvist, R. Cencic, F. Robert

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

266

254 INVITED Small molecule inhibitors of the human MDM2-p53 interaction as anticancer agents

S. Wang, S. Shangary, Q. Qin, D. McEachern, K. Ding, Z. Nikolovska-Coleska, Y. Lu, S. Malek, M. Guo, D. Yang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

267

255 POSTER Cytostatic effect induced by 2-chloroadenosine sensitises PC3 cells to docetaxel

I. Bellezza, A. Tucci, C. Conte, A. Minelli

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

268

256 POSTER SiRNA-mediated Apollon gene silencing induces apoptosis in breast cancer cells via p53 stabilization and caspase-3 activation

M. Pennati, A. Lopergolo, P. Gandellini, M. Folini, M.G. Daidone, N. Zaffaroni

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

269

257 POSTER Inhibition of autophagy significantly enhances the anticancer activity of SAHA by promoting ubiquitin-conjugated protein accumulation and oxidative stress in colon cancer cells

J. Carew, E. Medina, M. Mita, A. Mita, F. Giles, S. Nawrocki

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

270

258 POSTER Apoptosis and oxidative stress induced by 2-chloroadenosine in PC3 cell line

A. Tucci, I. Bellezza, C. Conte, A. Minelli

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

271

259 POSTER Histone deacetylase inhibitors restore caspase-8 expression and overcome TRAIL resistance in cancers with epigenetic silencing of caspase-8

S. Häcker, K.M. Debatin, S. Fulda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

272

260 POSTER A novel paradigm for apoptosis-based therapy of pancreatic cancer: sensitizer/inducer concept of XIAP inhibitors combined with TRAIL

M. Vogler, H. Walczak, D. Stadel, F. Genze, P. Möller, T. Simmet, K.M. Debatin, S. Fulda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

273

261 POSTER The Bcl-2 family protein inhibitor, ABT-263, broadly potentiates the cytotoxicity of multiple therapeutic agents in vitro and in vivo

C. Tse, J. Chen, S. Jin, V. Abraham, P. Nimmer, S. Tahir, M. Smith, H. Zhang, S. Rosenberg, S. Elmore

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

274

262 POSTER Membrane androgen receptor induced apoptosis in prostate cancer cells is regulated by Rho/ROCK/actin signaling

C. Stournaras, N. Papadopoulou, I. Charalambopoulos, A. Gravanis, K. Alevizopoulos

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

275

263 POSTER IGF-1 receptor stimulation overrides microenvironment-derived tumour cell quiescence

A.H. Kyle, J.H.E. Baker, F. Moosvi, A.I. Minchinton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

276

264 POSTER A novel arsenical, darinaparsin, induces apoptosis in arsenic trioxide-resistant and MRP1/ABCC1-overexpressing cell lines

K.K. Mann, Z. Diaz, S. Marcoux, M. Kourelis, M. Colombo, P.B. Komarnitsky, G. Abbadessa, W.H. Miller Jr.

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

277

265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis

S.V. Holt, A. Logie, B.R. Davies, M. Cockerhill, N. Haupt, N.J. Curtis, D.M. Hickinson, J.S. McKay, P.D. Smith, R.W. Wilkinson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

278

266 POSTER Apoptosis induction in acute myeloid leukemia by inhibition of MEK and MDM2 is strongly associated with the BH3-only proteins Puma and Bim

W. Zhang, M. Konopleva, J. Burks, K. Dywer, W. Schober, J. Yang, T. McQueen, M. Hung, M. Andreeff

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

279

267 POSTER Small molecule XIAP inhibitors enhance TRAIL- or anticancer drug-induced apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance

M. Fakler, S. Löder, M. Vogler, I. Jeremias, K.M. Debatin, S. Fulda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

280

268 POSTER Chemoresistance in ovarian carcinoma: apoptosis checkpoints in taxol-induced molecular pathways

A. Luria, M. Wolfson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

281

269 POSTER Recombinant human epidermal growth factor (rhEGF) inhibits proliferation of cancer cell lines with high level of EGFR expression

E.K. Kwon, S.H. Lee, H.G. Wu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

282

270 POSTER (E)-3-Benzyl-6, 8-dihydroxyoct-2-en-4-one, a novel compound isolated from Streptomyces sp., induces apoptosis in LNCaP cells through mitochondrial-mediated pathway

E. Jeon, H. Lim, Y.H. Cho, C.H. Lee, H. Oh

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

283

271 POSTER Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors

Y. Mishima, Y. Terui, Y. Mishima, A. Taniyama, R. Kuniyoshi, T. Takizawa, S. Kimura, K. Ozawa, K. Hatake

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

284

272 POSTER Activity of the anti-cancer aptamer AS1411 includes regulation of Bcl-2 family members

S. Kuijper, B. Doran, N. Courtenay-Luck, F. McLaughlin, D. Jones

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

285

273 POSTER A novel monosaccharide-based antimetabolite 2,2-difluoro-D-glucose (2-DFG) blocks glycolysis and induces cell death in gliomas

L. Antonovic, I. Fokt, M.J. Johansen, S. Szymanski, S. Skora, C.A. Conrad, T. Madden, W. Priebe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

286

274 POSTER Preliminary evidences for recruitment of innate responses to rectal cancer cell death elicited by neo-adjuvant radio-chemo therapy

A. Tamburini, A. Castiglioni, K. Bencardino, E. Orsenigo, V. Russo, L. Albarello, M. Ronzoni, P. Rovere Querini, A. Manfredi, C. Staudacher

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

287

275 POSTER Influence of 2-methoxyestradiol on cell numbers, metabolic activity, morphology, cell cycle progression and gene expression in a breast adenocarcinoma cell line

A.M. Joubert, B.A. Stander, S. Marais, J. Janse van Vuuren, F. Joubert

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

288

276 POSTER Platinum (IV) complex LA-12 induces cell cycle arrest and phase specific apoptosis in colon carcinoma cells HCT116

O. Blanarova, I. Jelinkova, R. Jendzelovsky, K. Soucek, J. Hofmanova, P. Sova, A. Kozubik

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

289

277 POSTER Expression of the genes involved in apoptosis, proliferation and endoplasmic reticulum stress in ionomycin/PMA treated Jurkat cells

K. Stankov, S. Tauszig-Delamasure, G. Bogdanovic, L. Popovic, S. Stankov, N. Sylvius, S. Popovic, P. Mehlen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

290

278 POSTER New curcumin analogues show enhanced antitumour activity in malignant melanoma cells

M. Pisano, S. Cossu, I. Sassu, G. Pagnan, D. Fabbri, M.A. Dettori, G. Palmieri, G. Delogu, M. Ponzoni, C. Rozzo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

291

279 POSTER MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial

A. Cervantes, T. Macarulla, S. Roselló, E. Rodríguez-Braun, J. Baselga, J. Tabernero, H. Liu, A. Chakravarty, D. Bowman, O. Eton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

292

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

J. Infante, E.C. Dees, R.B. Cohen, H. Burris, B. O'Neil, P. Murphy, Y. Lee, J. Pappas, J.A. Ecsedy, O. Eton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

293

281 POSTER Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

E. Dees, J.R. Infante, R.B. Cohen, B. O'Neil, H. Burris, M. von Mehren, G. Gray, K. Galvin, M. Manfredi, O. Eton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

294

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

P. Schöffski, H. Dumez, S.F. Jones, C. Fowst, P. Gerletti, H. Xu, J. Jakubczak, J. Infante, N. Mellaerts, H.A. Burris

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

295

283 POSTER Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients

F. Robert, H. Hurwitz, H. Uronis, C. Verschraegen, R. Advani, A. Chen, G.L. Messerschmidt, N. Havrilla, P. Taverna, M. Evanchik

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

296

284 POSTER ENMD-2076 exerts antiangiogenic and antiproliferative activity against human colorectal cancer (CRC) xenograft models

J.J. Tentler, E.L.B. Pierce, N.J. Serkova, T.M. Pitts, M.R. Bray, G.C. Fletcher, S.G. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

297

285 POSTER MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study

J. Tabernero Caturla, A. Cervantes, E. Elez, T. Macarulla, S. Roselló, E. Rodríguez-Braun, B. Stringer, V. Shinde, H. Danaee, O. Eton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

298

286 POSTER Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237

M.A. Smith, P.J. Houghton, C.L. Morton, J.M. Maris, J. Courtright, H. Carol, R.B. Lock, Y. Yang, M.G. Manfredi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

299

287 POSTER Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity

S. Howard, V. Berdini, J. Curry, A.L. Gill, C.J. Richardson, D. Rees, M. Reule, D. Tisi, P. Wyatt, L. Fazal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

300

288 POSTER The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines

B. Helfrich, M. Garcia, J. Haney, P.A. Bunn Jr.

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

301

289 POSTER Aurora A kinase inhibition abrogates the mitotic delay induced by microtubule perturbing agents

D.R. Wysong, A. Chakravarty, K. Hoar, J.A. Ecsedy

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

302

290 POSTER Pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Aurora kinases

A. Gavai, D. Norris, G. Trainor, G. Vite, Y. Zhao, D. Vyas, J. Tokarski, W. Han, T. Wong, B. Rupnow

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

303

291 POSTER Discovery of selective CDK9 small molecule inhibitors: CDK9 inhibition in tumor cells is associated with inhibition of proliferation and induction of apoptosis

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

304

292 POSTER AZD5597, a novel CDK inhibitor causes inhibition of RNA polymerase II mediated signaling and stimulates apoptosis in vitro and in vivo

S. Loddick, A. Barker, K. Blades, S. East, J. Foster, C. Geh, C. Jones, A. McGregor, D. Rudge, P.B. Simpson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

305

293 POSTER The complexity of cell cycle dynamic of anticancer drugs unraveled by the use of mathematical models suitable for a quantitative assessment of G1, S and G2M checkpoint activities

P. Ubezio, M. Lupi, C. Natoli, V. Colombo, M. D'Incalci

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

306

294 POSTER Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125

R. Alzani, C. Albanese, G. Locatelli, W. Pastori, N. Amboldi, W. Croci, F. Fiorentini, F. Roletto, C. DePonti, C. Mercurio

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

307

295 POSTER Growth inhibition and induction of apoptosis in anaplastic large cell lymphoma cells treated with the CDK inhibitor flavopiridol

P. Bonvini, E. Zorzi, L. Mussolin, G. Monaco, G. Basso, A. Rosolen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

308

296 POSTER Human glioblastoma organotypic slice culture: A novel model for the study of tumor biology and therapeutic response

V.K. Puduvalli, J. Xu, Y. Liu, F.F. Lang, S. Prabhu, G. Rao

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

309

297 POSTER In vivo efficacy and replication dynamics of intravenously administered oncolytic reovirus in nude mice bearing human melanoma xenografts

S. Sei, J. Mussio, S. Borgel, M. Hollingshead

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

310

298 POSTER Autocrine activity of tumor-derived membrane vesicles

B.S. Hong, E.J. Choi, E.Y. Lee, Y.J. Yoon, Y.S. Gho

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

311

299 POSTER Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted in a significant anti-tumoural response

C.A. Taylor, B. Ye, Z. Liu, R. Dondero, B. Galton, K.A. Donovan, J.A. Lust, J.E. Thompson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

312

300 POSTER Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104

D.C. Singleton, S.P. Syddall, S.Y. Bai, D. Li, W.A. Denny, W.R. Wilson, A.V. Patterson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

313

301 POSTER Use of low molecular weight polyethyleneimine conjugated to transferrin for siRNA delivery

A. Grabowska, R. Kircheis, J. Kumari, P. Clarke, A. McKenzie, S.A. Watson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

314

302 POSTER Identification of novel and potent RNA inhibitors of ErbB3, based on Locked Nucleic Acid (LNA) technology

M. Hedtjärn, J. Worm, H. Frydenlund Hansen, T. Koch, H. Ørum, J.B. Hansen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

315

304 POSTER Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

G.R. Simpson, A. Horvath, K. Harrington, R.S. Coffin, H. Pandha

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

316

305 POSTER Structure–activity relationships for lipophilic dinitrobenzamide mustards as prodrugs for Escherichia coli NfsB nitroreductase

S. Sydall, A. Ashoorzadeh, G.A. Atwell, J.B. Smaill, W.R. Wilson, W.A. Denny, A.V. Patterson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 66 KB

english, 2008

317

306 POSTER Targeted suicide gene therapy for small cell lung cancer

C. Laulund Christensen, N. Pedersen, H. Skovgaard Poulsen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 66 KB

english, 2008

318

307 POSTER Effects of triple knockdown of cIAP-1, c-IAP-2 and XIAP on prostate cancer cell susceptibility to apoptosis

W. Watson, C. Gill, A. O'Neill, C. Dowling, J. Fitzpatrick

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 82 KB

english, 2008

319

308 POSTER Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model

L. Heinemann, G. Simpson, K. Harrington, A. Melcher, M.C. Coffey, H.S. Pandha

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

320

309 POSTER Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models

M. Treder, S. Ogbagabriel, R. Moor, U. Schulze-Horsel, T. Hettmann, M. Rothe, R. Radinsky, D. Freeman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

321

310 POSTER ERBB2/HER2 proteasome–lysosome trafficking and degradation directed by polyubiquitination topology

C. Benz, C. Marx, J. Held, B.W. Gibson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

322

311 POSTER In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor

A. Iwahara, T. Tamura, S. Takagi, H. Kamiguchi, T. Yusa, Y. Ohta

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

323

312 POSTER EZN-3920, an ErbB3-locked nucleic acid-based RNA inhibitor, potently silences target gene expression in tumor cells grown in vitro and in vivo

B. Liao, T. Qu, J. Kosek, S. Castaneda, P. Sapra, Y. Zhang, R. Bandaru, L.M. Greenberger, I.D. Horak

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

324

313 POSTER Novel inhibitory mechanisms of TAK-285, a new EGFR/ErbB2 dual inhibitor

S.A. Shell, K.J. Pry, P. Trusk, R.L. Wappel, Y. Ohta, W. Klohs, S.S. Bacus

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

325

314 POSTER Combined antitumor efficacies of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor, with other anticancer drugs

T. Tamura, S. Takagi, K. Horikoshi, T. Yusa, M. Koyama, H. Tojo, Y. Ohta

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

326

315 POSTER A novel pan-HER ligand trap based on human EGFR (HER1) and HER3 inhibits tumor growth and metastasis in models of human cancer

Z. Huang, H.M. Shepard, D. Maneval, P. Jin, M. Beryt, J. Zhang, C. Brdlik, L. Cousens, B. Jorgensen, X. Bai

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

327

316 POSTER ErbB4 suppresses proteasomal degradation of HIF-1a and promotes survival of cancer cells in hypoxia

I. Paatero, S. Heikkinen, E. Iivanainen, T.T. Junttila, P. Heikkinen, O. Kallioniemi, P. Jaakkola, K. Elenius

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

328

317 POSTER Antiproliferative effects of PM02734, a novel marine cyclic peptide compared with currently used Erb-B inhibitors, in a panel of human cancer cell lines characterised for Erb-B expression

M. Serova, I. Bieche, A. Ghoul, M. Vidaud, M. Aracil, J. Jimeno, S. Faivre, E. Raymond

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

329

318 POSTER Downregulation of thymidylate synthase by lapatinib: blockage of EGF-induced translocation of nuclear EGFR and HER2

H. Kim, S. Han, K. Lee, J. Jung, Y. Yoon, H. Hur, S. Im, D. Oh, Y. Bang, T. Kim

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

330

319 POSTER Pharmacodynamics and anti-tumour activity of KU-0063794, a potent and specific inhibitor of mTOR kinase

B.R. Davies, C.M. Chresta, P. Dudley, N. Hewitt, M. Brady, M. Jacobsen, I. Hickson, N.M.B. Martin, G.C.M. Smith, M. Pass

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

331

320 POSTER Cellular characterization of OXA-01, a potent and selective dual mTORC1 and mTORC2 kinase inhibitor

S.V. Bhagwat, A.P. Crew, P.C. Gokhale, A. Cooke, J. Kahler, Y. Yao, A. Chan, L.D. Arnold, R. Wild, J.A. Pachter

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

332

321 POSTER A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules

L. Berk, D. Miller, D. Clapham, J. Loewy, M. Mita, C. Britten, E. Poplin, C.L. Bedrosian, T. Clackson, V.M. Rivera

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

333

322 POSTER mTORC1/mTORC2 selective inhibitors: Identification and characterization of novel small molecules with anti-tumor activity

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

334

323 POSTER Dependence on PI3K and RAS–RAF pathways drives the activity of the combination of RAD001 and RAF265, a novel inhibitor of the RAF-MAPK pathway

P. Mordant, C. Leteur, J. Bourhis, J.C. Soria, E. Deutsch

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

335

324 POSTER Synergistic activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) and the anti-androgen bicalutamide in prostate cancer models

R. Squillace, D. Miller, S. Wardwell, F. Wang, T. Clackson, V. Rivera

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

336

325 POSTER Erlotinib, an EGFR kinase inhibitor, sensitizes mesenchymal-like tumor cells to the actions of OXA-01, a selective non-macrolide inhibitor of mTORC1/mTORC2

S. Barr, S. Russo, S. Bhagwat, A. Crew, K. Iwata, D. Epstein, J. Pachter, M. Miglarese

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 70 KB

english, 2008

337

326 POSTER Dose-finding study of pegylated liposomal doxorubicin (PLD) and the mTOR inhibitor RAD001 (R) in patients (pts) with advanced solid tumors

C. Sessa, A. Perotti, A. Delmonte, G. Del Conte, E. Gallerani, A. Fasolo, F. Zanaboni, A. Locatelli, E. Dall'O', L. Gianni

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

338

327 POSTER The serine 2481-autophosphorylated form of mTOR directly binds the mitotic apparatus to control breast cancer cell proliferation: A new role of mTOR as mitotic checkpoint in cell cycle progression

J. Menendez, C. Oliveras-Ferraros, A. Vazquez-Martin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

339

328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

M. Javle, D. Fogelman, A. Kaseb, G. Varadhachary, R. Wolff, J. Abbruzzese

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

340

329 POSTER Vorinostat significantly enhances the antitumor activity of temsirolimus in renal cancer

S. Nawrocki, E. Medina, J. Esquivel, S. Smith, K. Oberheu, M. Mita, A. Mita, F. Giles, J. Carew

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 99 KB

english, 2008

341

330 POSTER Preclinical evidence for the effectiveness of mTOR inhibitor, nanoparticle albumin-bound (nab®) rapamycin as an anticancer agent

V. Trieu, T. De, A. Yang, J. Cordia, B. Grim, S. Ci, P. Nguyen, N. Desai

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 84 KB

english, 2008

342

331 POSTER CYP1A1 activation and pharmacokinetics of a novel chloromethylpyrrollolindoline with potential as a tumour selective prodrug

A.D. Race, K. Pors, S.D. Shnyder, T.C. Cooper, H.M. Sheldrake, M. Searcey, L.H. Patterson, P.M. Loadman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 84 KB

english, 2008

343

332 POSTER In vivo activity of SGI-1776, an orally active Pim kinase inhibitor

D. Bearss, E. Gourley, X.H. Liu, J. Bearss, C. Jones, C. Olsen, D. Vollmer, S. Warner, H. Vankayalapati, P. Severson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 101 KB

english, 2008

344

333 POSTER Effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human osteosarcoma and melanoma tumours

M. Pasello, F. Michelacci, F. Pellizzari Tregno, S. Pezzola, G. Filomeni, C. Geroni, M. Serra, G. Federici, C. Lapenta, A.M. Caccuri

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

345

334 POSTER Molecular modelling and synthesis of novel CYP26A1 inhibitors

A.S. Mohamed Aboraia, M.S. Gomaa, C. Simons

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

346

335 POSTER Identification of potent, selective sphingosine-1-phosphate 1 receptor (S1P1R) antagonists with antitumor activity

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 87 KB

english, 2008

347

336 POSTER Targeting MKP1 with novel chemical inhibitors sensitizes melanoma and colon cancer cells to chemotherapeutics in vitro and in vivo

S. Kundu, D. Lindner, R. Tuthill, G. Stark, L. Liu, S. Gerson, E. Borden, T. Yi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

348

337 POSTER GSK923925A, a novel and selective CENP-E inhibitor, induces pharmacodynamic effects and anti-tumor activity in human Colo205 xenografts

D. Sutton, Q. Liu, K.G. Moss, K.W. Wood, J.R. Jackson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

349

338 POSTER The ghrelin receptor agonist TZP-101 is a potent anti-tumor-cachexia agent in the human G361 melanoma mouse xenograft model

H. Thomas, N. Berthiaume, E. Kneebone, L. Clohs, E. Fournier, M.L. Peterson, E. Marsault, R. Brandt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 85 KB

english, 2008

350

339 POSTER Identification of XL413, a selective Cdc7 kinase inhibitor which induces cell cycle arrest and exhibits potent antitumor activity

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

351

340 POSTER Anti-tumor activity of YM753, a histone deacetylase inhibitor, against hormone refractory prostate cancer

M. Mori, N. Shindoh, N. Amino, A. Kita, Y. Terada, M. Taniguchi, K. Sohda, Y. Sowa, T. Sakai, M. Sasamata

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

352

341 POSTER CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity

D. Drygin, A. Lin, M. Haddach, C. Ho, J. Bliesath, C. Proffitt, M.T.K. Schwaebe, W.A.K. Rice, K.L. Anderes

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

353

342 POSTER 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography is an early biomarker for tumor growth inhibition of human Colo205 xenografts by the novel and selective CENP-E inhibitor, GSK923295A

D. Sutton, R.A. Fleming, K.W. Wood, J.R. Jackson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

354

343 POSTER Preclinical validation of the TrpM8 ion channel as a cancer target

D.F. Duncan, N. Provost, O. Moreno, M.W. Frohlich, D. Urdal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

355

344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

C. van Herpen, F. Eskens, M. de Jonge, I. Desar, L. Hooftman, E. Bone, A. Timmer-Bonte, J. Verweij

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

356

345 POSTER Myofibrillogenesis regulator 1 as a potential target for cancer therapy

R. Shao, K. Ren, Y. Wang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

357

346 POSTER Myofibroblasts and TGF-beta1 induce upregulation of tumoral L1CAM thereby promoting malignant transformation of pancreatic ductal epithelial cells

S. Sebens, C. Geismann, M. Morscheck, D. Koch, H. Ungefroren, A. Arlt, M.S. Tsao, M.G. Bachem, P. Altevogt, H. Schäfer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

358

347 POSTER Anti-cancer activity of human ribonuclease conjugates with enhanced pharmacokinetic profiles

L. Strong, B. Mei, J. Kink, M. Shahan, R. Raines

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

359

348 POSTER Molecular pharmacology of benzamide riboside and sodium meta arsenite in chronic myeloid leukemia: a preclinical evaluation

I. Hariharan, T.R. SantoshKumar, R. Hariharan, J.N. Hiremagalur, M.R. Pillai

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

360

349 POSTER Vorinostat sensitizes colorectal cancer cell (CRC) lines to AZD6244 and results in synergistic inhibitory effects on proliferation

M.P. Morelli, A.M. Meyer, J.J. Tentler, T.M. Pitts, S. Nallapareddy, P.D. Smith, S.G. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

361

350 POSTER Measurement of mechanistic markers of histone deacetylase (HDAC) inhibition in samples from clinical trials

A. Hardcastle, P. Fong, L. Pickard, J. Arts, M. Janicot, P. Hellemans, J. DeBono, W. Aherne

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

362

351 POSTER Identification of kinases that are potential molecular determinants of cellular response to radiation using antibody arrays

U. Raju, O. Riesterer, D. Molkentine, L. Milas, K.K. Ang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

363

352 POSTER Small molecule antagonists of very late antigen (VLA)-4 inhibit metastasis formation and tumor growth of melanoma

M. Valcarcel, F. Aspichueta, R. Hernan, M. Solaun, V. Gutierrez, L. Mendoza

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 78 KB

english, 2008

364

353 POSTER Therapeutic potential of YM155 alone and in combination with chemotherapeutics against human non-small cell lung cancer in carcinoma xenograft models

K. Yamanaka, T. Nakahara, A. Kita, S. Miyoshi, A. Noda, M. Takeuchi, I. Kinoyama, H. Koutoku, S. Nishimura, M. Sasamata

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

365

354 POSTER Membrane androgen receptor activation triggers down-regulation of PI-3K/AKT/NF-úB activity and induces apoptotic responses via FasL, caspase 3 and Bad in DU145 prostate cancer cells

K. Alevizopoulos, N. Papadopoulou, I. Charalambopoulos, V. Anagnostopoulou, A. Gravanis, C. Stournaras

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

366

355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449

C.M. Rudin, D.D. Von Hoff, P.M. LoRusso, L. Vernillet, R. Yauch, W.C. Darbonne, H. Mackey, F.J. de Sauvage, J.A. Low, J.C. Reddy

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

367

356 POSTER MLN4924, a potent and novel small molecule inhibitor of Nedd8 activating enzyme, induces DNA re-replication and apoptosis in cultured human tumor cells

M. Milhollen, U. Narayanan, B. Amidon, A. Berger, S. Langston, T. Soucy, P. Smith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

368

357 POSTER Effects of 5-fluorouracil (FUra)/leucovorin(LV)-induced DNA damage on the Wnt signaling pathway and downstream targets in human colon carcinoma cell lines (cc)

J. Houghton, T.S. Jani, C. Kundu, Y. Jiang, J. DeVecchio, P. Howe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

369

358 POSTER 18F-FLT-PET for the evaluation of MEK inhibitor AZD6244

I. Desar, R. Gilles, A. Timmer-Bonte, M.V. Cantarini, C.M.L. van Herpen, W.J.G. Oyen, W.T.A. van der Graaf

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

370

359 POSTER A role for tumor associated macrophages in tumorigenesis

A. Bonde, S. Zoller, R. Schwendener

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

371

360 POSTER Ror2 in renal cell carcinoma: evaluating its role in RCC tumorigenesis

T.M. Wright, J.D. Gordan, W.K. Rathmell

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

372

361 POSTER FGFR4 Y367C: Contributes to a constitutively active FGFR4 and tumour aggressiveness in breast cancer cell line

P. Foo, H.K. Ho, S. Streit, J.E. Ruhe, S. Hart, A. Ullrich

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

373

362 POSTER STAT3 protein binding to supercoiled DNA

S. Chasovskikh, O. Timofeeva, A. Dritschilo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

374

363 POSTER Fatty acid synthase is a potential therapeutic target in Micro-satellite-instable colorectal cancers

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

375

364 POSTER Obatoclax in SCLC: preclincal evaluation of a BH3 mimetic

E. Dean, M. Ranson, D. Fennell, A. Roulston, J. Viallet, M. Berger, C. Dive

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

376

365 POSTER Effects of PPARgamma agonists on adrenocortical carcinoma in a murine xenograft model

M. Mangoni, G. Nesi, S. Gelmini, A. Lombardi, G. Cantini, F. Malentacchi, C. Orlando, M. Luconi, M. Serio, M. Mannelli

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

377

366 POSTER NAV3 gene aberrations in colorectal cancer target signalling pathways associated with inflammation and the progression of cancer

E. Carlsson, K. Ovaska, L. Sipilä, M. Helle, W. Abdel-Rahman, L. Karenko, P. Peltomäki, S. Hautaniemi, K. Krohn, A. Ranki

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

378

367 POSTER Characterization of cellular resistance mechanisms towards NAD synthesis inhibitors APO866 and CHS-828

U.H. Olesen, M.K. Christensen, F. Björkling, P.B. Jensen, M. Sehested, S.J. Nielsen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

379

368 POSTER Discovery and characterization of a new potent orally available Cdc7 inhibitor with anti-tumor activity

A. Montagnoli, E. Vanotti, S. Rainoldi, V. Marchesi, A. Ciavolella, V. Croci, V. Patton, C. Albanese, C. Santocanale, J. Moll

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

380

369 POSTER Molecular sequelae mediating antitumor activity of G-quadruplex- interactive agent TMPyP4 in retinoblastoma cell lines

Y. Mikami-Terao, M. Akiyama, T. Kawano, H. Ida, H. Yamada

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

381

370 POSTER Once weekly rIL-21 in combination with cetuximab as 1st line therpay in CRC. A dose finding safety trial

J. Cassidy, A. Anthony, B. Esmarck, E. Ehrnrooth, P. Kristjansen, A. Nihlen, L.T. Hansen, M. Saunders

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

382

371 POSTER Toxicology and pharmacokinetics of humanized AR47A6.4.2, the first unconjugated therapeutic monoclonal antibody targeting TROP-2

N. Chouinard, S.E. Hahn, A.H.L. Truong, L. Popp, X. Wang, D. Sayegh, V. Harris, B.C. Mak, D.B. Rubinstein, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

383

372 POSTER Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumours

T. Takahashi, T. Naka, M. Fujimoto, S. Serada, Y. Souma, E. Miyoshi, S. Hirota, T. Nishida

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

384

373 POSTER HP1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers

M. Takanashi, K. Oikawa, T. Mizutani, N. Gotoh, M. Kuroda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

385

374 POSTER Efficient LNA-mediated antagonism of the oncogenic microRNA-155 in vitro and in vivo

J. Worm, J. Stenvang, S. Obad, M. Hedtjärn, E.M. Strarup, J.B. Hansen, S. Kauppinen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

386

375 POSTER Annexin I regulation of breast cancer cell proliferation

T. Khau, M. Schuliga, T. Harris, A. Stewart

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

387

376 POSTER NAV3–anovel cancer biomarker

L. Sipilä, L. Karenko, L. Siggberg, W. Abdel-Rahman, M. Helle, V. Häyry, S. Knuutila, P. Peltomäki, A. Ranki, K. Krohn

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

388

377 POSTER Selective inhibition of Stat3 expression induces apoptosis in human cutaneous T-lymphoma cell line Hut78

N.K. Verma, A.M. Davies, A. Long, D. Kelleher, Y. Volkov

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

389

378 POSTER CD147 expression correlates with monocarboxylate transporters 1 and 4 in cervical carcinoma

C. Pinheiro, A. Longatto-Filho, S.M.M. Pereira, D. Etlinger, M. Moreira, L. Jubé, F. Schmitt, F. Baltazar

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 94 KB

english, 2008

390

379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)

R. Kurzrock, S. Sherman, D. Hong, C. Ng, J. Frye, L. Janisch, M.J. Ratain, R. Salgia

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 80 KB

english, 2008

391

380 POSTER Transcriptional and metabolic response associated with acute doxorubicin cardiotoxicity in perfused rat heart

M. Tokarska-Schlattner, E. Lucchinetti, M. Zaugg, L. Kay, S. Gratia, R. Guzun, V. Saks, U. Schlattner

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 80 KB

english, 2008

392

381 POSTER Detecting EGFR mutations in NSCLC by mutant specific antibodies

J. Yu, S. Kane, J. Wu, D.Q. Li, X.M. Zhou, K. Crosby, H. Herbert, T.L. Gu, R. Polakiewicz, M. Comb

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 93 KB

english, 2008

393

382 POSTER Comparison of phase I trial (P1T) abstract quality between the EORTC-NCI-AACR and ASCO meetings

J. Ho, E. Strevel, N. Chau, G.R. Pond, A. Murgo, P. Ivy, L.L. Siu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

394

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

G.K. Schwartz, S. Yazji, D.S. Mendelson, M.A. Dickson, S.H. Johnston, E.W. Wang, P. Shannon, L. Pace, M.S. Gordon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

395

384 POSTER Effect of selection of QTc formula on eligibility of patients for phase I cancer clinical trials

M. Benjamin, D. Casa, W. Tembe, B. Piper, S. Anthony, R. Ramanathan, R. Tibes, G. Jameson, D. Von Hoff, M. Borad

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

396

385 POSTER A phase I safety, pharmacokinetic and pharmacodynamic study of carfilzomib, a selective proteasome inhibitor, in subjects with advanced solid tumours

K.P. Papadopoulos, J.R. Infante, A.F. Wong, L.A. Kunkel, A. Patnaik, M. Goldston, S. Mersch, S.D. Demo, A. Tolcher, H.A. Burris

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

397

386 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of an oral c-Met inhibitor ARQ197 reaches maximum tolerated dose (MTD) in a twice daily (bid) dosing schedule

T.A. Yap, J. Barriuso, S. Frentzas, R. Riisnaes, J. Clark, J. Dukes, A. Futreal, R.E. Savage, F. Chai, J.S. de Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

398

387 POSTER Operation strategy of Phase I trials

N. Ishizuka, T. Taniguchi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

399

388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma

S. Postel-Vinay, S. Okuno, S. Schuetze, M.L. Paccagnella, D. Yin, A. Gualberto, F. Worden, P. Haluska, J. De Bono, M. Scurr

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

400

389 POSTER Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors

I. Duran, L.L. Siu, C. Kollmannsberger, L. Gontovnick, S. Leong, L. Wang, C. Braun, T. Borgford, S.G. Eckhardt, L. Gore

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

401

390 POSTER A Phase I dose-escalation study of XL228, a potent IGF1R / Src inhibitor, in patients with advanced malignancies

C. Britten, D.C. Smith, L.A. Bui, D.O. Clary, H.I. Hurwitz

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

402

391 POSTER A Phase I randomized trial to assess the effects of Src inhibitor AZD0530 on renal function in healthy volunteers

R. Chetty, N. Dalton, M. Rimmer, N. Cockburn, I. Smith, A. Swaisland, J. Hargreaves, M. Stuart

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

403

392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib

J.C. Soria, E. Felip, R. Herbst, N. Hannah, S. laurie, J.P. Armand, F. Shepherd, D. Berman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

404

393 POSTER First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

J.E. Ang, B. Hauns, A. Mais, A. Parker, R. Lal, D. Olmos, M. Mollenhauer, A. Walz, J.S. de Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

405

394 POSTER Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

H. Murakami, N. Yamamoto, N. Boku, K. Yamazaki, N. Yamamoto, Y. Yamada, K. Yamada, T. Puchalski, E. Shin, T. Tamura

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

406

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

A. Tse, S. Yazji, A. Naing, D. Matthews, G. Schwartz, K. Lawhorn, R. Kurzrock

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

407

396 POSTER Effect of oral (PO) casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics (PK) and safety profile of intravenous (IV) docetaxel

L. Adams, B. Johnson, J. Bauman, P. Lebowitz, K. Zhang, T. Webb, E. Gartner, R. Hohl, U. Dandamudi, L. Lewis

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

408

397 POSTER A phase I dose escalation and pharmacokinetic study of the novel mitotic checkpoint inhibitor GSK923295A in patients with solid tumors

R.A. Fleming, K.D. Holen, T.L. Cyr, B.M. Johnson, J.L.S. Gauvin, J.J. Lager, B. Williams, D.B. Alberti, B.L. Weber, V. Chung

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

409

398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours

N. Lewis, R.B. Cohen, Y. Nishida, H.I. Hurwitz, C. Arrowwood, H.E. Uronis, F. Gamza, C. Longley, A. Buchbinder, J. Figueroa

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

410

399 POSTER A Phase 1 dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of intravenous LY2275796 (LY), an eIF-4E antisense oligonucleotide (ASO) in patients with advanced solid tumors

G.R. Simon, M. Fishman, A.M. Dellaportas, D. Sullivan, L.H. Brail, V. Andre, S. Callies, U. Aytac, D. Hong, Y. Oh

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

411

400 POSTER Early evidence of tolerability and clinical activity from a phase 1 study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer

L.S. Rosen, M.S. Gordon, H.I. Hurwitz, D.S. Mendelson, D. Kleinzweig, B.J. Adams, C.P. Theuer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

412

401 POSTER A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies

H.A. Wakelee, S.K. Padda, L. Chhatwani, M. San Pedro-Salcedo, Y. Krupitskaya, L. Musib, J.E. Latz

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

413

402 POSTER A phase I study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies

S. Leong, C.L. Obryant, W.A. Messersmith, S. Diab, M.A. Kane, S. Nallapreddy, C. Weekes, J. Spratlin, J. Call, S.G. Eckhardt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

414

403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial

A.W. Tolcher, M. Mita, M. Gordon, L. Rosen, A. Patnaik, G.D. Fine, G.S. Choy, G.I. Berk

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 78 KB

english, 2008

415

404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors

W. Kelly, D. Petrylak, G. Blumenschein, U. Lassen, P. Buhl Jensen, J. DeBono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

416

405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers

S.J. Hotte, H.W. Hirte, P. Moretto, A. Iacobucci, D. Wong, W. Korz, W.H. Miller

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

417

406 POSTER IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study

S. Krishnamurthi, P.H.B. Goncalves, F. Fox, N. Hall, E. Rowinsky, J. Schwartz, H. Youssoufian, P. LoRusso

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 81 KB

english, 2008

418

407 POSTER Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studies

D. Zain, D. Bongero, A. Goy, R. Orlowski, J. Hainsworth, B. Afanasyev, M.M. Chen, R. Escandon, Y. Mao, O.A. O'Connor

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

419

408 POSTER Phase 1 study of recombinant human Interleukin-21 (rIL-21) in combination with sunitinib in patients with stage IV renal cell carcinoma

V. Grünwald, I. Desar, J. Haanen, W. Fiedler, M.B. Olsen, C.M.L. van Herpen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

420

409 POSTER A Phase I clinical trial of the oral PPAR gamma agonist, CS-7017 in patients with advanced malignancies

M.J. Pishvaian, A. Wagner, J. Deeken, A.R. He, J. Hwang, S. Malik, I. Cotarla, G. Demetri, J.L. Marshall, S. Wojtowicz-Praga

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

421

410 POSTER Phase I pharmacodynamic (PD) and pharmacokinetic (PK) analysis of the sorafenib (S) and erlotinib (E) combination in patients with advanced solid tumors

C. Le Tourneau, I. Duran, E. Chen, L. Wang, M. Tsao, D. Hedley, N. Phan, T. Do, U. Metser, L. Siu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

422

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

R. Salgia, A. Peterson, S. Eppler, W. Yu, B. Polite, D. Geary, E. Wesolowski, M. LaRosiliere, M. Ratain, M. Sovak

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

423

412 POSTER A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug

G.J. Weiss, J.R. Infante, M. Borad, V.K. Langmuir, S. Kroll, D. Jung, R. Tibes, E.G. Chiorean, S.F. Jones, H.A. Burris

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

424

413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

W.P. Yong, B.C. Goh, K. Ethirajulu, P. Yeo, O. Otheris, S.M. Chao, R. Soo, W.L. Yeo, E. Seah, J. Zhu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

425

414 POSTER A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors

M.S. Gordon, L.S. Rosen, F. Robert, D.S. Mendelson, D. Kleinzweig, B.J. Adams, C.P. Theuer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

426

415 POSTER Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations

Y. Lee, O. Eton, J. Pappas, S. Chen, M. Paton, E.C. Dees, S. Jones, R.B. Cohen, A. Cervantes, J. Tabernero

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

427

416 POSTER Phase I trial of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies: updated safety profile and maximum tolerated dose

A.R. Tan, T. Mekhail, M.J. Edelman, L.C. Iacono, M. Messina, O.C. Trifan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

428

417 POSTER Phase I study of E7389/Gemcitabine combination in patients with advanced solid tumours

R. Goel, L. Vidal, S. Welch, S. Laurie, L. Siu, D. Jonker, R. Srinivasan, L. Wang, C. Fortin, A.M. Oza

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

429

418 POSTER A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT)

M.J. Pishvaian, J.H. Hwang, S. Malik, A.R. He, J.F. Deeken, C.B. Kelso, K. Dorsch-Vogel, M.S. Berger, J.L. Marshall

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 80 KB

english, 2008

430

419 POSTER A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours

M. Sorensen, J. Tjørnelund, P.B. Jensen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

431

420 POSTER A phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS)

A.T. Brunetto, A. Krarup-Hansen, O.S. Nielsen, A. Norman, A. Safwat, J. Tjørnelund, I. Judson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

432

421 POSTER Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour

T. Mukohara, S. Nagai, Y. Nambu, K. Yoshizawa, H. Minami

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

433

422 POSTER A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumours

N. Okamoto, K. Hatake, N. Yamamoto, S. Takahashi, N. Boku, K. Kobayashi, K. Sakatani, T. Hirashima, K. Matsui

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

434

423 POSTER Phase I dose escalation study of NK012, polymer micelle of irinotecan metabolite SN-38, in patients with advanced cancer

D. Toshihiko, N. Fuse, A. Ohtsu, Y. Matsumura, T. Hamaguchi, K. Kato, Y. Shimada, T. Nakajima, Y. Yamada, M. Takanashi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

435

424 POSTER ANG1005, an Angiopep-2/paclitaxel conjugate: the first clinical trial in patients with advanced cancer and brain metastases: Preliminary safety and tolerability data

R. Kurzrock, S. Fu, A.C. Mita, Z. Guo, C. Allison, D. Bouchard, K.M. Elian, A. Neale, J.P. Castaigne, J. Sarantopoulos

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

436

425 POSTER ANG1005: Preliminary clinical safety and tolerability in patients with recurrent malignant glioma

J.P. Castaigne, K.M. Elian, D. Bouchard, A. Neale, S. Rosenfeld, J. Drappatz, M. Groves, P. Wen, P. Bento, B. Lawrence

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 102 KB

english, 2008

437

426 POSTER Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules

J. Kissling, G.D. Fine, G.S. Choy, C. Eddy, G.I. Berk

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 87 KB

english, 2008

438

427 POSTER Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I dose-escalation study

A. Patnaik, M. Goldston, C. Takimoto, A. Tolcher, K. Papadopoulos, T. Bekaii-Saab, B. Kleiber, F. Gamza, C. Longley, A. Buchbinder

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 87 KB

english, 2008

439

428 POSTER A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors

Y. Onozawa, N. Boku, A. Fukutomi, A. Ohtsu, T. Doi, T. Yoshino, W. Koizumi, S. Tanabe, T. Sasaki

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 104 KB

english, 2008

440

429 POSTER Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors

H. Hurwitz, P. LoRusso, G.I. Shapiro, A. Wolanksi, J. Chemidlin, E. Masson, S. Syed, G. Kollia, K. Conlon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

441

430 POSTER Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer

D. Rudolph, M. Steegmaier, M. Hoffmann, M. Grauert, A. Baum, J. Quant, P. Garin-Chesa, G. Adolf

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

442

431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors

S. Blagden, D. Olmos, R. Sharma, J. Barriuso, H. Medani, M. Versola, S. Murray, D.A. Smith, M.M. Dar, J.S. de Bono

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 80 KB

english, 2008

443

432 POSTER A small molecule allosteric inhibitor of Polo-like kinase 3 induces apoptosis and disrupts the integrity of the mitotic spindle apparatus in cancer cells

S.K. Horrigan, I. Lonskaya, P. Adiseshaiah, N.E. Ohler, Z. Weaver, Z. Wang, D.K. Bol, T. Lawrence, S. Chellappan, J.W. Strovel

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

444

433 POSTER Crystal structures of Plk1 kinase domain in complex with ATP-competitive inhibitors

I. Beria, J.A. Bertrand, M. Caruso, M. Fasolini, N. Mongelli, R. Perego, S. Re Depaolini, P. Storici, B. Valsasina, R. Bossi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

445

434 POSTER Antitumoral activity of pyrazoloquinazoline derivatives as potent oral Plk-1 specific inhibitors

I. Beria, B. Valsasina, M.G. Brasca, M. Caruso, R.D. Ferguson, J. Lansen, J. Moll, E. Pesenti, H. Posteri, M. Rocchetti

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

446

435 POSTER Therapeutic potential of a potent and selective antagonist of the MDM2-p53 interaction (MI-219) in combination with traditional chemotherapy

S. Shangary, D. McEachern, M. Liu, R. Miller, S. Qiu, Z. Nikolovska-Coleska, S. Wang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 80 KB

english, 2008

447

436 POSTER The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain

H. Kadri, T.C. Dale, K.B.R. Ewan, A.D. Westwell

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 135 KB

english, 2008

448

437 POSTER MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines

X. Lu, J. Liu, A. Watson, I.R. Hardcastle, R.J. Griffin, B.T. Golding, D.R. Newell, J. Lunec

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 135 KB

english, 2008

449

438 POSTER Pharmacodynamics (PD) of GRN163L in a Phase I study in refractory, solid tumors

M. Ratain, J.A. Smith, F.M. Benedetti, L. Elias, P. LoRusso

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

450

439 POSTER The cytotoxic activity of the telomere binding agent KML001 in non-small cell lung cancer cells is dependent on telomere length and p53 status and is enhanced by cisplatin

P. Phatak, M. Edelman, H. Hendriks, A. Burger

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

451

440 POSTER Integrative biological studies of antitumour agents

L.A. Johnson, A.E. Willis, H.M. Byrne, C.A. Laughton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

452

441 POSTER The G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors

A. Biroccio, M. Scarsella, A. Rizzo, M. Mottolese, M. D'Incalci, A. Stoppacciaro, M. Stevens, E. Gilson, G. Zupi, C. Leonetti

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

453

442 POSTER Novel small molecule inhibitors of telomerase

A. Adekunle, H.R. Evans, V.A. Phillips, D. Pletsas, R.T. Wheelhouse, S.M. Parkin, D.A.L. Watt, D.T.S. Sharpe, R.M. Phillips

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

454

443 POSTER Reduced expression of the epithelial specific ETS factor ESE-3 is associated with resistance to taxanes in prostate cancer cells

R. Cangemi, S. Pellini, P. Kunderfranco, A. Malek, C.V. Catapano, G.M. Carbone

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

455

444 POSTER BAL27862: a novel tubulin interacting agent with activity in multidrug resistant tumors and potential as a vascular disruption agent

H.A. Lane, J. Pohlmann, F. Bachmann, U. Lüdi, S. Mathews, J. Heim

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

456

445 POSTER Class III beta-tubulin overexpression in non-small cell lung, breast and prostate carcinoma xenografts confers innate or acquired resistance to taxanes and sensitivity to ixabepilone

F. Lee, K. Covello, M. Kimler, R. Lenhart, Y. She, S. Platero, R. Kramer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

457

446 POSTER A phase I study of eribulin mesylate (E7389) in patients with refractory cancers

H. Minami, T. Mukohara, S. Nagai, H. Mukai, M. Namiki

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

458

447 POSTER ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma

R. Woessner, B. Tunquist, E. Chlipala, M. Humphries, D. Trawick, A. Cox, P. Lee, J. Winkler, D. Walker

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 81 KB

english, 2008

459

448 POSTER NKTR-105, a novel PEGylated-docetaxel, demonstrates superior anti-tumor activity compared to docetaxel in human non-small cell lung and colon cancer xenografts

R. Wolff, S. Routt, J. Riggs-Sauthier, W. Zhang, H. Persson, R.K. Johnson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

460

449 POSTER In vivo evaluation of ALB 109564, a novel tubulin inhibitor with improved efficacy over existing members of the Vinca alkaloid class

M. Wolf, R.K. Johnson, D. Xie, A. Avrutskaya, R. Mullin, B. Godfrey, I. Scott

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

461

450 POSTER NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522

S. Neuteboom, E. Medina, M.A. Palladino, M.A. Spear, G.K. Lloyd, S. Nawrocki

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

462

451 POSTER Prednisolone abrogates patupilone (EPO906)-induced diarrhoea in rats without impacting on patupilone PK or efficacy

P. McSheehy, M. Becquet, J. Boisclair, M.N. Bizot

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

463

452 POSTER Tubulin acetylation and the antimotility effects of tubulin-targeting agents

K. Bonezzi, B. North, C. Manzotti, A. Riva, E. Verdin, R. Giavazzi, G. Taraboletti

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

464

453 POSTER Antitumor efficacy of a new taxane, nanoparticle albumin bound ABI-013

C. Tao, V. Trieu, Q. Wang, T. De, S. Ci, P. Nguyen, N. Desai

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

465

454 POSTER Combretastatin-induced changes in normal vascular physiology and the therapeutic implications

M. Horsman, A. Bohn, M. Skals, T. Wang, M. Busk

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

466

455 POSTER Comparison of the effect of patupilone (EPO906) and other cytotoxic drugs on interstitial fluid pressure (IFP) and growth of human ovarian (1A9 and 1A9PTX10) and lung (A549 and A549.B40) xenografts in athymic mice

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 52 KB

english, 2008

467

456 INVITED Development of practical delivery systems for therapeutic small RNAs

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

468

457 INVITED Identifying mechanisms of drug resistance using large scale genetic screens

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

469

458 INVITED High-throughput RNAi screening using cell microarray technology

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

470

459 INVITED microRNA and therapeutic applications

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

471

460 INVITED Update on imaging tumor proliferation with PET

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

472

461 INVITED Hypoxia imaging

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

473

462 INVITED Apoptosis imaging

H. Strauss, F. Blankenberg

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

474

463 INVITED Applications of nanotechnology and molecular probes in cancer imaging

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

475

464 INVITED Antibodies/antibody conjugates in development

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

476

465 INVITED Challenges in the development of antibody drug conjugates

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

477

466 INVITED Challenges in targeting proteases as anti-cancer therapy

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

478

467 INVITED The targeted oncology platform at ImClone Systems: novel receptor blocking antibody therapeutics and approaches

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

479

468 POSTER The role of thymidine kinase and thymidylate synthase in the response of tumor cells to the suicide prodrug 2′-F-ara-deoxyuridine

P. Phatak, C.M. Daniels, A.F. Shields, J.M. Collins, P.M. LoRusso, A.M. Burger

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

480

469 POSTER The nucleoside analogue sapacitabine (CYC682) synergises with histone deacetylase inhibitors in multiple tumour types

I.N. Fleming, A.K. Choudhary, R.H. Mackay, S.R. Green, S. Davis

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

481

470 POSTER Target identification permits rational development of the prodrug GMX1777 for the treatment of melanoma

M. Watson, A. Roulston, H. Chan, D. Goulet, D. Bedard, E. Turcotte, G. Shore, J. Viallet, P. Beauparlant

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

482

471 POSTER Plasma pharmacokinetics of CP-4055 in patients with acute myeloid leukaemia at the recommended phase II dose

S. Hagen, S.M. O'Brien, T.F. Jacobsen, H.M. Kantarjian, M.L. Sandvold, F. Giles

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 78 KB

english, 2008

483

472 POSTER The IMPDH inhibitor AVN944 synergizes with Clofarabine to induce cell death in myeloid cancer cell lines

J. Strovel, T. Lawrence, P. Natarajan, J.M. Hamilton, D.K. Bol

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

484

473 POSTER The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase)

A.V. Patterson, C.P. Guise, M. Abbattista, W. van Leeuwen, S.M. Pullen, D.M. Ferry, W.A. Denny, P. Guilford, W.R. Wilson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

485

474 POSTER Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models

R.S. Singleton, S.M. Pullen, D.M. Ferry, C.P. Guise, A.V. Patterson, W.R. Wilson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

486

475 POSTER Sustained co-cultivation with human placenta-derived MSCs enhances ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation and inhibition of proliferation

Y.A. Young, M.H. Kang, J.S. Kim, J.H. Seo

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

487

476 POSTER Involvement of the helix-loop-helix protein ID-1 in granulocytic differentiation of human myeloblastic leukemia cells

T. Shimizu, K. Takeda

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

488

477 POSTER Sequence-selective inhibition of the DNA binding potencies of Pit-1 and Brn-3 transcription factors by phenyl-furan-benzimidazole DNA ligands

P. Peixoto, S. Depauw, M.P. Hildebrand, D.W. Boykin, W.D. Wilson, M.H. David-Cordonnier

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

489

478 POSTER Human cancer cells are sensitized to voreloxin (formerly SNS-595) after modulation of DNA double strand break repair

R. Kimmel, J. Kumer, D. Stockett, R. Hawtin, P. Taverna, J. Silverman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

490

479 POSTER Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications

T.D. Bradshaw, J. Zhang, M.F.G. Stevens, C.A. Laughton, S. Madhusudan, P. Kirschmeier

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

491

480 POSTER MP-470, a novel multi-targeted tyrosine kinase inhibitor targeting rad51 is not toxic to human primary marrow stem cells at clinically relevant concentrations

R. Joshi, S. Kanekal, S. Redkar, G. Berk

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 65 KB

english, 2008

492

481 POSTER Expression of genes involved in DNA damage response pathways in ovarian cancers

G. Damia, M. Ganzinelli, P. Mariani, R. Fruscio, C. Mangioni, M. Broggini

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

493

482 POSTER Pre-clinical pharmacology of the novel PARP inhibitor, AZD2281 (KU-0059436)

A.N. Cranston, S. Moore, L. Beaudoin, A. Lau, L. Lewis, L. Copsey, M.J. O'Connor, K.A. Menear, G.C.M. Smith, N.M.B. Martin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

494

483 POSTER Immunohistochemical DNA repair expression profile breast cancer: correlation with clinical-pathological features

S. Costa, F. Milanezi, M. Duarte, J. Paredes, A.L. Correia, A. Longatto-Filho, F. Schmitt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

495

484 POSTER EGFR mutations and gefitinib affinity: molecular insights from in silico experiments

S. Pricl, G.M. Pavan, M. Fermeglia, E. Tamborini, M.A. Pierotti, S. Pilotti

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

496

485 POSTER Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

A. Kong, V. Calleja, P. Leboucher, A. Harris, P. Parker, B. Larijani

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

497

486 POSTER Combined targeting of DNA repair and AKT survival pathways enhance temozolomide therapeutic activity in melanoma

L. Liu, Y. Miao, A. Bulgar, B. Jacobs, M. Schluchter, E. Borden, S. Gerson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

498

487 POSTER An inducible expression system to study the EGFR-T790M gefitinib-resistance mutation in a human lung cancer cell line

F. Moreira-Leite, A. Welman, R.A.R. Roberts, C. Dive

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

499

488 POSTER MDR-transporters, namely Pgp, MRP1 and vault protein LRP, as poor predictive markers of tamoxifen efficiency in estrogen receptor positive breast cancer tumours

E.A. Dudko, E.A. Bogush, T.A. Bogush, V.J. Kirsanov, G.Y. Tchemeris, M.I. Davydov

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 91 KB

english, 2008

500

489 POSTER Casein kinase II modulates topoisomerase II alpha nuclear export and drug sensitivity of multiple myeloma cells

J.G. Turner, J. Dawson, B. Fang, J. Koomen, D.M. Sullivan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

501

490 POSTER Examination of the mechanisms associated with bortezomib- resistance in human multiple myeloma cell lines

D.J. Kuhn, R.Z. Orlowski

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

502

491 POSTER AF1q enhancement of doxorubicin induced apoptosis in human squamous carcinoma A431 cells

N.N. Co, W.P. Tsang, T. Wong, T.Y. Tsang, T.T. Kwok

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

503

492 POSTER Role of human epidermal receptor targeted therapies in chemo-sensitization of oesophageal adenocarcinoma cells

L. Campbell, S. Van Schaeybroeck, J. Kyula, M.M. Eatock, P.G. Johnston

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

504

493 POSTER Manipulating prostate cancer cell susceptibility to docetaxel and novel titanocene analogues induced apoptosis

C. Dowling, S. Cuffe, M. Tacke, J. Fitzpatrick, W. Watson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

505

494 POSTER Cellular and molecular patterns associated with sensitivity and resistance to enzastaurin in human cancer cells

A. Ghoul, M. Serova, I. Bieche, M. Videau, K.A. Benhadji, S. Faivre, E. Raymond

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

506

495 POSTER Enhanced expression of Annexin IV in clear cell carcinoma of the ovary and its association with chemo-resistance

A. Kim, S. Serada, K. Iwahori, Y. Souma, T. Takahashi, T. Naka

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

507

496 POSTER Regulation of Nrf2-antioxidant system and glutathione transferases by 5-fluorouracil in colon cancer HT-29 cells: potential implication in drug resistance

H. Akhdar, P. Loyer, C. Rauch, A. Guillouzo, F. Morel

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

508

497 POSTER Different patterns in telomerase activity (TA) change after acquisition of resistance to tamoxifen in hormonal receptor positive breast cancer cells

W. Park, J. Joo, Y. Jung, H. Jeon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

509

498 POSTER Interleukin-8 signalling contributes to chemotherapy resistance in colorectal cancer cells

C. Purcell, C. Wilson, O. Oladipo, R.H. Wilson, P.G. Johnston, D.J. Waugh

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

510

499 POSTER The effects of hypoxia on the sensitivity of glioma cells to gemcitabine treatment

R. Foster, S. Mead, K. Grimshaw

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

511

500 POSTER Molecular and cellular consequences of glyceraldehyde-3-phosphate- dehydrogenase (GAPDH) direct interaction with the S23906–1/DNA adduct

G. Lenglet, S. Depauw, D. Mendy, A. Pierré, M.H. David-Cordonnier

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

512

501 POSTER MicroRNA expression profiling in paclitaxel-resistant ovarian cancer cell line: miR-31 is involved in the acquired resistance to paclitaxel

M. Hassan, H. Watari, A. Abdel Kader, T. Mitamora, N. Sakuragi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

513

502 POSTER Modification of cisplatin administration schedule in FLEP preoperative chemotherapy improved response to the chemotherapy in patients with locally-advanced esophageal cancer

T.A. Bogush, B.E. Polotskiy, E.A. Bogush, I.A. Pokataev, E.O. Ignatova, S.A. Tjulandin, M.I. Davydov

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

514

503 POSTER ABCG2 transporter gene expression in childhood rhabdomyosarcoma

H.P. McDowell, S. Marsilio, P. Altavista, S. Bosco, A. Donfrancesco, A. Inserra, P.D. Losty, C. Dominici

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

515

504 POSTER GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in Non-Hodgkin lymphoma xenograft models and superior B cell depletion

C. Klein, F. Herting, T. Friess, C. Gerdes, A. Nopora, S. Bauer, R. Grau, E. Moessner, J. Dal Porto, P. Umana

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

516

505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases

A. Macias, E. Neninger, E. Santiesteban, J. Figueredo, A. Hernandez, F. Aguirre, N. Aguilera, T. Crombet

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

517

506 POSTER The apogenic anti-CD9 antibody, AR40A746.2.3, inhibits tumor growth in breast and pancreatic cancer and targets cancer stem cells in acute myeloid leukemia

J. Menendez, L. Jin, A.G. Poeppl, K. O'Reilly, R.H. Brunet, J. Grabell, A.K. Gupta, J.E. Dick, D.S. Pereira, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

518

507 POSTER Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate hBU12-vcMMAE in rituximab sensitive and resistant lymphomas

H.P. Gerber, I. Stone, M. Kung-Sutherland, J. Miyamoto, N. Okeley, S.C. Alley, D.L. Meyer, D. Sussman, P. Senter, I.S. Grewal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

519

508 POSTER PDL192, a novel, humanized antibody to TWEAK receptor, shows potent anti-tumor activity in preclinical models

P. Culp, D. Choi, J. Yin, S. Tan, D. Chao, M. Su, M. Sho, R. Steinle, E. Hsi, V. Ramakrishnan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

520

509 POSTER Efficacy of AMG 479, a fully human anti-IGF-1R monoclonal antibody, against xenograft models displaying genetic alterations in Ras/Raf, PI3K/PTEN and p53 pathways

P.J. Beltran, G. Moody, P. Mitchell, Q. Le, B. Belmontes, E. Cajulis, Y.A. Chung, F. Calzone, R. Radinsky

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

521

510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours

P. Woll, F. Fossella, M. O'Brien, Y. Clinch, K. Donaldson, J. O'Keeffe, S. Zildjian, R. Fram, A. Qin, P. Lorigan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

522

511 POSTER Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies

E. Chiorean, C. Sweeney, H. Youssoufian, F. Fox, T. Katz, E. Rowinsky, R. Amato

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

523

512 POSTER Interim results from a Phase 1/2 study of volociximab in combination with liposomal doxorubicin in patients with advanced epithelial ovarian or primary peritoneal carcinoma that relapsed after platinum/taxane chemotherapy

P. Antonella, C. Sessa, A. Delmonte, G. Del Conte, A. Fasolo, E. Dall'O', F. Zanaboni, S. Watkins, K. Smith, L. Gianni

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

524

513 POSTER Anti-tumor effect of an anti-human Müllerian Inhibiting Substance type II receptor antibody in a nude mouse model for granulosa cell tumors: a new targeted therapy for ovarian cancer

N. Kersual, V. Garambois, I. Salhi, C. Larbouret, F. Bibeau, C. Mollevi, T. Chardès, A. Pèlegrin, I. Teulon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

525

514 POSTER A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (HUC242-DM4) in gastric cancer

A. Tolcher, J. Watermill, R.A. Mastico, R.J. Lutz, J. O'Keeffe, S. Zildjian, A. Phan, A. Mita, A. Qin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

526

515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel

T. Junttila, C. Fields, G. Li, L. Crocker, K. Parsons, L. Berry, K. Totpal, G. Lewis Phillips, M. Sliwkowski

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

527

516 POSTER Efficacy of EGFR and IGF-1R antibody therapy is independent of PTEN status in a selection of tumor models

D. Deevi, D. Burtrum, M. Melchior, L. Witte, D.L. Ludwig, J.R. Tonra

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

528

517 POSTER A monoclonal antibody (AR36A36.11.1) with potent in vivo efficacy in multiple human cancer models targets CD59

B. Mak, F. McConkey, N. Feng, K. O'Reilly, S.W. Fung, M. Wang, S. Chau, S.E. Hahn, D.S. Pereira, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

529

518 POSTER Novel antibody-maytansinoid conjugates with efficacy against multidrug resistant tumors

Y. Kovtun, C. Audette, E. Maloney, M. Mayo, G. Jones, H. Erickson, S. Wilhelm, R. Singh, V. Goldmacher, R. Chari

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 62 KB

english, 2008

530

519 POSTER A phase 2, single-arm study of volociximab (an anti-a5b1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer

C.M. Matthews, S.N. Ho, M. Barve, K.M. Bell-McGuinn, L. Gilbert, R.T. Penson, E. Lengyel, S. Weymer, K. Gilder, R.J. Schilder

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 79 KB

english, 2008

531

520 POSTER A monoclonal antibody targeting Trop-2 exhibits anti-tumor efficacy in human cancer models as a monotherapy and demonstrates efficacy in combination therapy

A.H.L. Truong, M. Wang, V. Harris, N. Aziz, J. Grabell, L. Popp, M. Amoozgar, S.E. Hahn, D.S. Pereira, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

532

521 POSTER A monoclonal antibody targeting the breast cancer stem cell marker melanoma-associated chondroitin sulfate proteoglycan improves survival and demonstrates anti-tumor activity in vivo

A.K. Gupta, A. Ferry, M. Amoozgar, C. Vieira, D. Sayegh, J. Menendez, N. Ceric, L.A.G. da Cruz, D.S. Pereira, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

533

522 POSTER Discovery of the 6F4 anti-tumor antibody targeting the tight junction molecule JAM-A. 1. Target identification by proteomic approach

J.F. Haeuw, L. Goetsch, L. Zanna, M. Malissard, V. Robillard, A.M. Lepecquet, A. Robert, C. Bailly, N. Corvaïa

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 92 KB

english, 2008

534

523 POSTER Combination of the anti-CD30–auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin lymphoma

H.P. Gerber, E. Oflazoglu, K. Kissler, D. Kennedy, E.L. Sievers, N.C. Ihle, D.L. Meyer, I.S. Grewal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

535

524 POSTER New biomolecule for cancer therapy

E. Campigna, C. Germain, S. Morisseau, J.P. Mach, A. Pèlegrin, B. Robert

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

536

525 POSTER Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer

C. Carrigan, C. Zuany-Amorim, M. Mayo, D. Tavares, R. Lutz, A. Kellogg, V. Blanc, P. Vrignaud, M. Bissery, G. Payne

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

537

526 POSTER Prediction of clinical response of rituximab containing chemotherapy using newly established live-cell-imaging procedure for estimating CDC susceptibility

Y. Mishima, Y. Terui, N. Sugimura, Y. Mishima, K. Hatake

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

538

527 POSTER Improving the therapeutic window of antibody-drug conjugates through novel linker design

D.L. Meyer, S.O. Doronina, T.D. Bovee, J.B. Miyamoto, M.E. Anderson, I.J. Stone, C.A. Morris-Tilden, H.P. Gerber, P.D. Senter

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

539

528 POSTER Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information

H. Xiang, A. Reyes, M. Merchant, B. Bender, N. Jumbe, J. Young, T. Gelzleichter, A. Vaidyanathan, A. Peterson, L. Damico

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

540

529 POSTER Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models

C.A. Vater, C. Manning, H. Millar, F. McCabe, Q. Chen, G.M. Anderson, R. Steeves, K. Lai, R.J. Lutz

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 74 KB

english, 2008

541

530 POSTER Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients

T. Crombet Ramos, J. Figueredo, M.T. Salomón Cárdenas, J.C. Selva Infante, C. Toledo Jiménez, J. Vaquer, N. Quintanal, S. Salva Camaño, R. Odelín Tablada, J.J. Marinello

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

542

531 POSTER Junctional complexes as a factor limiting the extravascular penetration of trastuzumab

K.E. Lindquist, J.T. Sy, A.H. Kyle, J.H. Baker, A.I. Minchinton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

543

532 POSTER A chimerized anti-CD4 monoclonal antibody for the treatment of T cell lymphomas acts through activation of membrane acid sphingomyelinase leading to increased ceramide release and CD4/ZAP-70 protein redistribution in membrane rafts

M. Chentouf, M. Rigo, A. Pèlegrin, T. Chardès

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

544

533 POSTER In vivo stability in mice of SAR566658 (huDS6-DM4), an immunoconjugate targeting solid tumours

M.F. Mayo, A.P. Leung, L. Wang, P. Wunderli, G. Payne, H. Xie, R.J. Lutz

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

545

534 POSTER Expression profiling demonstrates co-stimulatory activity of BMS-663513, an anti-CD137 antibody

H. Chang, L. Obenauer-Kutner, A.Q. He, G. Xing, A. Truong, P. Kayne, A. Flesher, N. Siemers, M. Jure-Kunkel, M. Grace

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

546

535 POSTER Characterization of a fully human PDGFRa antibody that reduces tumor growth and stromal infiltration in a xenograft model of non-small cell lung cancer

N. Laing, B. McDermott, S. Wen, M. Pandya, A.M. Mazzola, D. Lawson, P. Hall, A. Drake, S. Klakamp, Z. Cao

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

547

536 POSTER Comparison of the tumor growth inhibitory effects of tumor cell and non-tumor cell EGFR targeted antibodies in cancer models

D. Surguladze, M.J. Plym, I. Duignan, M. Prewett, D.J. Hicklin, Y. Wu, L. Witte, J.R. Tonra

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

548

537 POSTER Detection of EGFR mutation in the sample of pleural effusion is contributive as a determinant of EGFR-TKI-therapy for the patients with lung cancer

A. Uchida, T. Shibayama, S. Takahashi, N. Hamada, N. Kawata, A. Tada, R. Soda, K. Takahashi

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

549

538 POSTER ARH460-16-2, targeting the CD44 cancer stem cell marker, uses multiple mechanisms to achieve its therapeutic anti-cancer effects

L.A.G. da Cruz, K. O'Reilly, F. McConkey, X.W. Wang, T. Antoshchenko, N. Aziz, A.K. Gupta, S.E. Hahn, D.S. Pereira, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

550

539 POSTER Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb

B. Bender, H. Xiang, A.E. Reyes II, L.A. Damico, M. Merchant, A. Peterson, W. Forrest, N.L. Jumbe

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 55 KB

english, 2008

551

540 POSTER Allogeneic MHC Class I conjugated to antitumor antibody can induce regression of syngenic tumor grafted in vivo

S. Morisseau, V. Cesson, P. Guillaume, E. Campigna, J.P. Mach, A. Pelegrin, B. Robert

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

552

541 POSTER Gemcitabine versus combined antibodies against EGF receptors in pancreatic cancer: preclinical findings for clinical development

C. Larbouret, B. Robert, C. Mollevi, F. Penault-Llorca, A. Ho-Pun-Cheng, M. Coelho, I. Teulon, A. Pèlegrin, D. Azria

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

553

542 POSTER Vascular endothelial growth factor receptor-1 (VEGFR1) immunoreactivity in human renal carcinoma

S. Wang, Y. Wu, L. Witte, J. Tonra

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

554

543 POSTER Location… location… location: hitting the functional epitope within the target is essential for anti-cancer antibody therapeutics

B.C. Mak, A.H.L. Truong, N. Feng, L.A.G. da Cruz, B.S. Mistry, S.W. Fung, T. Perez, S.E. Hahn, D.S. Pereira, D.S. Young

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 84 KB

english, 2008

555

544 POSTER Discovery of the 6F4 anti-tumor antibody targeting the tight junction molecule JAM-A. 2. Target expression on human tumors and in vitro and in vivo anti-cancer activity

L. Goetsch, J.F. Haeuw, A. Gonzalez, C. Beau-Larvor, L. Zanna, T. Wurch, C. Bailly, N. Corvaïa

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

556

545 POSTER Enhancement of cell motility with radiation-induced VEGF in glioma

W. Kil, K. Camphausen

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

557

546 POSTER Gl261 brain tumor cells: responses to single or fractionated x-irradiation with the avb3 integrin thyroxine receptor antagonist TETRAC (tetraiodothyroacetic acid)

A. Hercbergs, P.J. Davis, M. Cieslieski, F. Davis, J.T. Leith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

558

547 POSTER Effect of the extract of Taraxacum officinale on inflammation induced by anti-cancer treatment

Y. Oh, S.H. Kang, M. Chun, E. Lee, E.H. Kim, J. Han, J. Yang

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 83 KB

english, 2008

559

548 POSTER Targeting non-coding promoter-associated RNAs in the c-myc gene with small interfering RNAs induce gene silencing and growth arrest in c-myc over-expressing cancer cells

C. Pastori, S. Napoli, M. Magistri, A. Sepe, F. Cavalli, G. Carbone, C. Catapano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

560

549 POSTER Quantitation/significance of MRD in standard risk adult ALL by RQ/PCR

N.K. Abousamra, D.M. Elghannam, D.A. Shahin, E.F. Goda, H. Azzam, E. Azmy, M. Salah El-Din

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

561

550 POSTER Designing nanovectors for siRNA delivery: coupled experimental/modeling investigations

S. Pricl, P. Posocco, G.M. Pavan, M. Fermeglia, G. Scocchi, A. Danani, A. Malek, S. Napoli, C.V. Catapano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

562

551 POSTER RNAi-based identification of potential targets in colorectal cancers

M. Grade, A.B. Hummon, J. Camps, G. Emons, M. Spitzner, J. Gaedcke, M.J. Difilippantonio, B.M. Ghadimi, N.J. Caplen, T. Ried

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

563

552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design

P.A. Janne, M. Wax, J. Leach, J. Engelman

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

564

553 POSTER AP24534: an orally active kinase inhibitor that targets multiple pro-angiogenic receptors and exhibits potent anti-tumor activity in vivo

V.M. Rivera, R. DiRenzo, L. Berk, S. Wardwell, Y. Ning, N.I. Narasimhan, Q. Xu, W.C. Shakespeare, F. Wang, T. Clackson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

565

554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies

M.L. Rothenberg, E. Poplin, P. LoRusso, E. Yu, J. Schwartz, F. Fox, J. Mehnert, A.B. Sandler, E. Rowinsky, C.S. Higano

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

566

555 POSTER The PARP inhibitor, ABT-888 overcomes resistance in temozolomide refractory breast and prostate xenograft tumors implanted in metastatic sites in vivo

J. Palma, L. Rodriguez, Y.W. Wang, G. Bukofzer, J. Hickson, T. Penning, V. Giranda, S. Rosenberg, D. Frost, C. Donawho

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

567

556 POSTER MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models

M. Mark, Y. Zhang, Y. Su, M.S. Romero, C. Severin, Z. Zheng, N. Mendoza, D.W. Kaufman, G.F. Vande Woude, E. Filvaroff

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

568

557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer

M.J. O'Connor, A. Lau, R.S. Finn, C. Knights, A. O'Shaughnessy, O. Kalous, D. Conklin, L. Riches, J. Carmichael, D.J. Slamon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 72 KB

english, 2008

569

558 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12

E.A. Kolb, C. Morton, P.J. Houghton, J.M. Maris, H.S. Friedman, S.T. Kier, R.G. Gorlick, M.H. Kang, C.P. Reynolds, M.A. Smith

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

570

559 POSTER The role of the ErbB3/PI3K/AKT pathway in determining breast cancer cell sensitivity against the irreversible dual EGFR/ErbB2 inhibitor EKB-569

W. Shabbir, C. Brünner-Kubarth, M. Grusch, W. Berger, B. Marian, R. Wagner, D. Lötsch, C.C. Zielinski, T.W. Grunt

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

571

560 POSTER Discovery and preclinical characterization of BMS-777607: a potent, small molecule inhibitor of Met receptor tyrosine kinase

R. Borzilleri, J. Fargnoli

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

572

561 POSTER Discovery and preclinical characterization of a series of novel JAK2 small molecule inhibitors for the treatment of myeloproliferative diseases

K.A. Jessen, S. Leonard, K. Froning, C. Tang, C. Smith, D. Ellis, S. Sperry, S. Gessert, S. Reich, S.G. Buchanan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

573

562 POSTER The anti-insulin-like growth factor I receptor antibody EM164 (murine AVE1642) enhances anti-tumor activity of temozolomide against neuroblastoma cell lines and xenografts

B. Geoerger, J.F. Brasme, E. Daudigeos, F. Bladt, C. Venot, L. Debussche, P. Vrignaud, G. Vassal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

574

563 POSTER SGX126: a novel, potent and highly selective small molecule inhibitor of the c-Met receptor tyrosine kinase

S. Buchanan, K. Jessen, C. Tang, S. Sperry, C. Smith, P. Bounaud, J. Hendle, P. Lee, S. Gessert, S. Reich

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

575

564 POSTER First-in-human (FIH) study of PF-00299804 in advanced cancer patients: correlation between pharmacokinetics (PK) and pharmacodynamics (PD)

J. Schellens, F. Guo, P.A. Jänne, S.G. Eckhardt, D.R. Camidge, I. Taylor, J. Lucca, D.S. Boss, S.G. Wong, C.D. Britten

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 83 KB

english, 2008

576

565 POSTER Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial

J.S. De Bono, D.P. Petrylak, E. Calvo, F. Saad, G.R. Hudes, M.M. Cooney, M.N. Pollak, D.B. Agus, S. Gillessen, J. Scranton

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

577

566 POSTER Pyrazolo[3,4-d]pyrimidines as dual kinase inhibitors of both insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor receptor family (EGFR and ErbB-2)

R.D. Hubbard, N.Y. Bamaung, S.D. Fidanze, S.A. Erickson, G.T. Wang, R.A. Mantei, P. Kovar, J. Wang, G.S. Sheppard, R.L. Bell

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

578

567 POSTER GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models

A.G. Gilmartin, A.M. Kusnierz, D. Sutton, K.G. Moss, C.S. Thompson, B.L. Weber, R.A. Copeland, J.R. Jackson, S.G. Laquerre

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 69 KB

english, 2008

579

568 POSTER Selective inhibition of Met kinase activity impairs metastatic cancer cell motility and survival

M. Versele, T. Lavrijssen, C. Rockx, T. Geerts, B. Janssen, P. King, M. Page, T. Perera

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 82 KB

english, 2008

580

569 POSTER Preclinical studies and characterization of BMS-777607, a small molecule inhibitor of Met receptor tyrosine kinase

J. Fargnoli, R. Borzilleri

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

581

570 POSTER Activity of IPI-926, a novel inhibitor of the HH pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHH ligand

J. Sydor, V. Travaglione, I. Deyneko, Z. Oaks, M. Pink, J. Proctor, M. Read, K. McGovern, V. Palombella, J. MacDougall

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

582

571 POSTER Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a potent small molecule JAK2 inhibitor

C.E. Olsen, E.S. Gourley, X. Liu, H. Vankayalapati, D. Vollmer, P. Severson, J. Bearss, C. Jones, D.J. Bearss, S.L. Warner

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 64 KB

english, 2008

583

572 POSTER Astragalus saponins (AST) modulate mTOR and ERK signaling with NF-kappa B as target in native and cytokine-induced HT-29 colon cancer cells

J.K.S. Ko, N.L. Mok, C.M. Wong, K.K.W. Auyeung

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

584

573 POSTER Identification of potent, selective JAK2 inhibitors using a fragment-based screening approach

N.G. Wallis, G. Chessari, J.E. Curry, C. Hamlett, K.A. Lewry, J. Lyons, C.J. Richardson, D. Tisi, D. Walker, A.J. Woodhead

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

585

574 POSTER Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

K. Thress, T. MacIntyre, H. Wang, Z.Y. Liu, E. Hoffmann, T. Wang, D. Whitston, J.L. Brown, K. Webster, C. Omer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 59 KB

english, 2008

586

575 POSTER Targeting metastatic tumor cell functions by inhibition of new blood vessel formation with the selective VEGF signal inhibitor, cediranib (RECENTIN™, AZD2171) or Src signaling interference using the small molecule Src inhibitor, AZD0530

D.W. Siemann, M. Dong

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 73 KB

english, 2008

587

576 POSTER ARRY-768, a highly potent and selective small-molecule PDGFR inhibitor which inhibits cellular and in vivo tumor growth

T.C. Yeh, S. Allen, M. Callejo, A. Cox, N. Klopfenstein, S. Kragerud, M. Munson, J. Robinson, R. Woessner, F. Marmsater

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

588

577 POSTER Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer

J. Miner, C. Yu, C. Iverson, R. Hamatake, W. Cheney, M. Chapman, A. Adjei, B. Quart

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

589

578 POSTER RGB-286638 is a novel multitargeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models

M. Caligiuri, H. Loferer, L. Lamphere, N. Kley

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 57 KB

english, 2008

590

579 POSTER Biological and biochemical activity of TLN-4601 in pancreatic cancer

P.M. Campbell, J.J. Fiordalisi, A.B. Hanker, N. Boufaied, H. Gourdeau, P. Falardeau, A.D. Cox, C.J. Der

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 77 KB

english, 2008

591

580 POSTER RhoA and RhoB inversly modulate estrogen receptor alpha expression and transcriptional activities in breast cancer cell lines

E. Meunier, E. Malissein, E. Bouliong-Pillai, Y. Bergé, P. Balaguer, G.C. Prendergast, G. Favre, F. Dalenc, S. Doisneau-Sixou

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

592

581 POSTER Inhibition of protein kinase C as the molecular basis of the synergism between safingol and irinotecan in colon cancer treatment

L. Ling, H. Lin, N. Chiu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

593

582 POSTER An acquired point mutation in MEK2 causes resistance to allosteric MEK inhibitors

A.M. Kusnierz, A.G. Gilmartin, M.R. Bleam, T.X. Vilimas, S.J. Blakemore, W.S. Halsey, K.G. Moss, D. Sutton, J.R. Jackson, S.G. Laquerre

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

594

583 POSTER Analysis of MAP kinase signalling pathway in KIT & PDGFRA wild-type GISTs

O. Martinho, A. Gouveia, M. Viana-Pereira, P. Silva, A. Pimenta, R.M. Reis, J.M. Lopes

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 76 KB

english, 2008

595

584 POSTER Novel inhibitors of BRAF based on a 2,6-disubstituted pyrazine scaffold

I. Niculescu-Duvaz, E. Roman, S.R. Whittaker, F. Friedlos, R. Kirk, I.J. Scanlon, L.C. Davies, D. Niculescu-Duvaz, R. Marais, C.J. Springer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

596

585 POSTER Phase I study of the safety and pharmacokinetics of an oral, film-coated (FC) tablet of CP-868,596, a PDGFR inhibitor, in patients with advanced cancers

L. Lewis, N. Reddy, F. Guo, K.J. Pierce, A.J. Olszanski, S. Balan

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

597

586 POSTER Modulation of signaling through SEK1 and MKK7 differentially affects oxaliplatin sensitivity in hypoxic colon cancer cell lines

I. Vasilevskaya, D. Roberts, M. Selvakumaran, S. Johnson, P. O'Dwyer

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

598

587 POSTER Understanding the role of Raf signaling in B-Raf V600E mutant versus wildtype tumors

G. Hatzivassiliou, S. Sideris, I. Yen, S. Gloor, M. Callejo, B. Brandhuber, B. Liu, M. Belvin, S. Malek

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 75 KB

english, 2008

599

588 POSTER Bench to bedside – Bedside to bench: Preclinical determination of the potential pharmacological activities of vandetanib in the clinic

A.J. Ryan, R. Odedra, N. James, K. Ratcliffe, G. Marshall, Z. Howard, L. Jackson, D. Baker, N. Smith, S.R. Brave

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

600

589 POSTER Functional evaluation of members of the LIV-1 family of proteins and their role in breast cancer

N. Mohamad Zahari, K.M. Taylor, R.I. Nicholson

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

601

590 POSTER Molecular and antiproliferative effects of inhibitors of fatty acid synthase and of ErbB receptors in ovarian cancer cells

T.W. Grunt, R. Wagner, W. Shabbir, W. Berger, B. Marian, M. Grusch, C.C. Zielinski, R. Lupu

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 58 KB

english, 2008

602

591 POSTER Antitumor activity of PLX4032, a selective V600EB-Raf inhibitor, as monotherapy and in combination with capecitabine ± bevacizumab in a colorectal cancer xenograft model

K. Kolinsky, G. Bollag, R. Lee, K. Packman, D. Heimbrook, F. Su, B. Higgins

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

603

592 POSTER Obatoclax (GX17–070), a small molecule pan-bcl-2 inhibitor, in combination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC)

A. Chiappori, C. Williams, D. Northfelt, J. Adams, S. Malik, M. Edelman, P. Rosen, D. Van Echo, M. Berger, E. Haura

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

604

593 POSTER Rational design of effective therapy combining irinotecan and rapamycin to target mTOR/HIF-1 alpha axis in colon cancer

E. Pencreach, M. Arrive, W. Raffelsberger, I. Lelong-Rebel, A.K. Larsen, M.P. Gaub, D. Guenot, E. Guerin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 60 KB

english, 2008

605

594 POSTER Enhanced anti-tumor effects of TP300, a novel camptothecin analogue, in combination with other anti-tumor agents in human tumor xenograft models

M. Endo, M. Ura, H. Tanimura, K. Taniguchi, Y. Miyazaki, S. Nagao, H. Okabe, M. Miwa

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

606

595 POSTER First Phase I trial of NKTR-102 (PEG-irinotecan) reveals early evidence of broad anti-tumor activity in three schedules

D.D. Von Hoff, G. Jameson, M.J. Borad, L.S. Rosen, J. Utz, S. Dhar, L. Acosta, T. Barker, J. Walling, J.T. Hamm

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 63 KB

english, 2008

607

596 POSTER The topoisomerase I inhibitor gimatecan exhibits synergistic activity with temozolomide and tyrosine kinase inhibitors in malignant glioma xenografts

B. Geoerger, N. Hamelin, P. Rodier, P. Opolon, R. Versace, G. Vassal

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 81 KB

english, 2008

608

597 POSTER Novel Topoisomerase 1 mutations in colorectal carcinoma cell lines are involved in SN38 resistance

C. Gongora, N. Vie, S. Tuduri, A. Causse, P. Martineau, P.H. Pourquier

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

609

598 POSTER Voreloxin (formerly SNS-595) is a potent DNA intercalator and topoisomerase II poison that induces cell cycle dependent DNA damage and rapid apoptosis in cancer cell lines

O.K. Wong, A. Conroy, N. Tan, W. Yang, R. McDowell, J.A. Fox, R.E. Hawtin

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

610

599 POSTER The iron chelator di-2-pyridylketone-4,4,-dimethyl-3- thiosemicarbazone causes DNA damage in breast cancer cells

V.A. Rao, S. Klein, K. Agama, Y. Pommier, E. Shacter

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 61 KB

english, 2008

611

600 POSTER Hematologic pharmacodynamics linked to the pharmacokinetics of berubicin (B), a blood–brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials

R. Kazerooni, C. Conrad, M.J. Johansen, M. Sakamoto, I. Fokt, C. Schroeder, N. Thapar, C. Meyer, W. Priebe, T. Madden

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 71 KB

english, 2008

612

601 POSTER Cross-trial analysis of immunological and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax®) in colorectal, renal and prostate cancer patients

R. Harrop, W.H. Shingler, N. Drury, M. Goonewardena, J. de Belin, S. Naylor, P. Treasure

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

613

602 POSTER An anti-idiotypic HER2 vaccine can reverse immunological tolerance to HER2 and induce anti-tumor immunity in huHER2 female transgenic mice

M.Z. Ladjemi, S. Corgnac, S. Morisseau, B. Robert, C. Mollevi, T. Charès, W. Jacot, A. Pèlegrin, I. Navarro-Teulon

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

614

Presenting authors list

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 67 KB

english, 2008

615

Author index

Journal:

European Journal of Cancer Supplements

Year:

2008

File:

PDF, 133 KB

2008

616

Subject index

Journal:

European Journal of Cancer Supplements

Year:

2008

File:

PDF, 116 KB

2008

617

303 POSTER Enhanced efficacy of therapy of anti-CD20 antibody with Locked Nucleic Acid antisense oligonucleotide targeting Bcl-2 in human Burkitt's lymphoma xenografts

Hansen, J.B., Høg, A.M., de Boisferon, M. Hillairet, Bichat, F., Hansen, H.F., Worm, J.

Journal:

European Journal of Cancer Supplements

Year:

2008

Language:

english

File:

PDF, 56 KB

english, 2008

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Tor version

Z-Library

Z-Library Since 2009 support@1delivery.pm

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски